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ABSTRACT 
THE DESIGN OF AN INSTRUMENT TO ASSESS CLINICAL LABORATORIES 
EFFICACY POST IMPLEMENTATION OF THE PATIENT  
PROTECTION AFFORDABLE CARE ACT 
by Harry McDonald Jr. 
May 2017 
The healthcare system in the United States has undergone substantial changes in 
support of the Patient Protection and Affordable Care Act (PPACA). On March 23, 2010, 
the implementation of the new healthcare law brought universal healthcare access to all 
Americans, while attempting to increase quality and decrease medical costs. The new law 
promotes more of a quality-focused, outcome-based model rather than a pay-for-fee 
service model; thus, moving the paradigm from infrequent to preemptive healthcare. The 
PPACA postulates as the only way to achieve cost savings while increasing quality and 
access. Never before has there been such an extensive change to the healthcare system 
since the inception of the Medicare system in 1965. In 2014, approximately 49 million 
uninsured Americans entered the healthcare system prompting increased demands of 
providers in navigating the new law; therefore, encouraging institutions to adopt best 
practices regarding health care reform. The purpose of this study is to begin assessing 
those best practices in clinical laboratories, by creating an accurate instrument, based on 
the theory of the iron triangle of health care. William Kissick first proposed the 
theoretical framework in 1994, when he conceptualized that healthcare 1) as a tightly 
linked, self-equilibrating system of three constructs: cost, quality, and access 2) when the 
increase occurs in one or two of the constructs, an effect to the third construct will occur. 
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As a reformer to healthcare in the laboratory, the PPACA maybe a disrupter to the theory, 
therefore this study addresses the effects of PPACA. One-Hundredth Sixty Clinical 
Laboratory Improvement Amendment (CLIA) affiliated laboratory managers from 50 
states provided data to validate the Clinical Laboratory Manager Inventory survey 
(CLMI). The data from the survey were analyzed using IBM SPSS 23 and AMOS 23 
software with the statistical methodology Structural Equation Modeling (SEM). The 
results of the study showed the CLMI explained 75% of the variance associated with 
PPACA effects on the laboratory, indicating that it is an accurate instrument and that 
PPACA acts as a disrupter to theory. This finding allows the laboratory community to 
have a plausible instrument to assess the impact of PPACA on subsequent research.  
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CHAPTER I - INTRODUCTION 
Dr. William Kissick once said, “The forecast for the year 2000 is that we will 
spend between 15 and 18 percent of the gross national product on health and medical 
care, and I am certain, 6 percent on education” (Godfrey, 2012, p 1). The cost of 
healthcare in America is a contentious debate for policymakers, medical administrators, 
healthcare providers, and patients. Gradually, the U. S. healthcare system is becoming the 
defining sector of the economy. In 1960, healthcare made up roughly 5% of the gross 
domestic product (Bandyopadhyay et al., 2013). In 2014, health care has reached a 
substantial portion of the gross domestic product (GDP) at 17.5%, approximately $3.1 
trillion annually (Center for Disease Control and Prevention [CDC], 2014). By 2020, 
expectations are that healthcare will account for 20% of the GDP with no signs of 
decreasing; as a consequent, new policies and reforms are necessary to decrease 
healthcare cost in the future (Bennett et al., 2014). Much of the U.S. public is convinced 
of having the greatest healthcare system in the world. As more data is gathered, this 
allegory slowly has begun to diminish. Although the practice of medical advances in the 
United States warrants recognition, these advancements have not translated into a 
superior healthcare system (Panning, 2014b). 
Of the $3.1 trillion attributed annually to healthcare cost, approximately 19.9% 
($597 billion) is spent on clinical and ancillary laboratory services (CDC, 2014). Some 
common causes of high health care expenditures include the fee-for-service payment 
system that depends on essential the quantity of healthcare and not its quality. This is 
because most physicians are in control of the decision-making process for healthcare 
purchases, thus they are not constrained in most healthcare settings by cost (Panning, 
 2 
2014a). Another factor is capitation payment practices that guarantee a set amount for 
each patient assigned for a time period regardless of whether or not the patient seeks care. 
Other factors that drive U.S. healthcare costs are private healthcare insurance companies 
practicing medical underwriting and risk selection to better position themselves to 
capitalize on their return of investment (Panning, 2014b). In the absence of council and 
policies that mandate health care insurers’ acceptance of all applicants, insurance 
companies pursue strategies to avoid high-risk patients. This is done by using extensive 
screening processes that are known to produce costly administrative fees to healthcare 
(Riegelman, 2011). The Institute of Medicine projects that approximately one-third of the 
U.S. healthcare expenditures are due to administrative costs and futile procedures 
(Lelflar, 2013). In addition to the increase in administrative costs, the growth in 
technology innovations appears to increase healthcare cost due to startup expenses that 
exacerbate currently strained budgets.  
According to most economists, assessments of healthcare systems employ the 
constructs of cost, access, and quality also known as the iron triangle of health care 
(Carroll, 2012). In the United States, healthcare cost is approximate $9,523 per capita, 
more than any other industrialized country in the world (CDC, 2014). In fact, the United 
States spends approximately 6% more on healthcare than the second highest country with 
high-cost health care expenditures (CDC, 2014). With these high costs, one would expect 
the United States to have the best access, and best outcomes of healthcare; however, this 
is a false narrative (Bandyopadhyay et al., 2013). At present, the United States ranks 
number one in health care cost but ranks 37th of developed nations with appropriate 
healthcare for citizens (Truman, 2013). In terms of access, the United States is one of the 
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three wealthiest nations that do not ensure that all of their citizens have universal 
healthcare. Because of this disappointing statistic, the U.S. government has implemented 
changes in the health care system in the form of the PPACA (Truman, 2013).  
Statement of the Problem 
The Patient Protection Affordable Care Act has a myriad of provisions that will 
affect health care on all levels. Among the numerous of regulations and changes is the 
implementation of the statute on clinical laboratories. The enactment of the statute 
appears to be a disrupter to the iron triangle of health care, based upon the three 
constructs of access, cost, and quality. Numerous clinical laboratorians and scientists, as 
well as the institutions that regulate them, are voicing their concerns regarding the impact 
of the PPACA. However assessing access, cost and quality in clinical laboratories is 
difficult due to the paucity of formal studies devoted to understanding their dynamics. 
Currently, there is not an instrument to assess the effects of the PPACA on clinical 
laboratories.  
Hence, the purpose of this study is to design a model that accurately assesses the 
three constructs (access, cost, and quality) for current and future applications. Structure 
equation model is the statistical method used to predict a plausible model assessing the 
constructs’ relationships between the predicted model and the observed data as a 
disrupter to the theory of the iron triangle. The goal of the study is to produce the most 
parsimonious instrument that represents the predicted structure model without sacrificing 
the comprehensiveness of the assessment. 
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The Patient Protection Affordable Care Act 
The goal of the PPACA is to increase access to health insurance for Americans 
while increasing quality and decreasing cost of healthcare. On March 23, 2010, Congress 
passed the PPACA and President Obama signed it into law (Bandyopadhyay et al., 2013). 
However, there was much opposition to passing this healthcare reform for fear of 
advocating socialized medicine, increasing cost, and partisan ideology (Lelflar, 2013). 
The PPACA was challenged on June 28, 2012 (National Federation of Independent 
Businesses et al. v. Sibelius, Secretary of Health and Human Services et al., 2012) 
nonetheless it was upheld by the Supreme Court 5-4 for all provisions (Lehman, 2015).  
One provision of the PPACA challenged in the courts was the mandate placed on 
non-exempt individuals who do not receive health insurance through an employer or 
government-sponsored program. These individuals must purchase insurance from a 
private insurer. Individuals that do not comply will be assessed a penalty collected by the 
Internal Revenue Service as a tax, beginning in 2014 (Internal Revenue Service [IRS], 
2014). The principle of this provision is to lessen the cost of insurance premiums by 
employing the economy of scale as a cost-saving strategy; assuring that everyone obtains 
insurance in order to seek affordable healthcare. The other key provision is the expansion 
of Medicaid. This provision expands the scope of the program, increasing the number of 
individuals the states must cover. Traditionally, states covered only underprivileged 
adults with children. Conversely, this provision of the PPACA requires states to provide 
Medicaid coverage to adults with incomes up to and below the 138% of the federal 
poverty level (Lehman, 2015). If an adult falls into this category, the PPACA provides 
federal funding to offset the cost to states for subsidizing the individual. However, if a 
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state refuses to comply with the new coverage it may lose all federal Medicare/Medicaid 
funds (IRS, 2014).  
The Patient Protection Affordable Care Act, also stipulates that poorer Americans 
and some middle-income American families, between the federal poverty line of 138% to 
400%, receive subsidies to make premiums more affordable (Woodward, 2012). Since 
2014, 32 states have opted into Medicaid expansion and 19 states have not for reasons of 
ideology, partisanship, culture, and fear that the expanded federal subsidies would 
overburden their state’ finances in the future (Lelflar, 2013).  
Other provisions include (a) prevention of insurance carriers from denying or 
rejecting coverage to sick individuals, (b) prevention of insurance carriers from charging 
unwarranted rates to seniors and the frequently ill, and (c) prevention of insurance 
carriers from imposing lifetime limits on benefits (Lehman, 2015). In addition, the 
PPACA mandates free preventive services and other anticipatory procedures making it a 
preemptive healthcare initiative (Lelflar, 2013).  
The series of provisions brought on by the PPACA have encouraged medical 
institutions; to generate best operational practices that foster an atmosphere of increase 
access and quality, while simultaneously decreasing cost. On the contrary, the iron 
triangle of health care, as an assessment tool regarding healthcare systems, fosters doubt 
to these claims. Therefore, it is necessary to address these assertions. 
The aim of this study is to develop a model based on the PPACA as a disrupter to 
the iron triangle and to design an instrument that will accurately assess healthcare 
efficacy in clinical laboratories, as it pertains to the theory post implementation of the 
PPACA. 
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Laboratory Clinical Services 
The first recorded history of clinical laboratory services was on human bodily 
fluids circa 300 BC, by the ancient Greek physician Hippocrates (Wolcott, Schwartz, & 
Goodman, 2008). In 1896, the first official clinical laboratory was opened at Johns 
Hopkins Hospital with the purpose of discovering diseases such as diphtheria, 
tuberculosis, cholera, and developing new methods to detect other maladies (Wolcott et 
al., 2008). The creation of these methodologies established the importance of clinical 
laboratory services in the 20th-century. In 1922, The American Society of Clinical 
Pathologists formed the first professional society supporting physicians specializing in 
pathology (Delwiche, 2003). In 1926, under the purview of physicians credited by the 
American College of Surgeons, all hospitals were required to establish clinical 
laboratories (Berger, 1999). Since then clinical laboratories have provided healthcare 
providers with objective information that assists in the prevention and diagnosis of 
healthcare concerns.  
Currently, there are over 250,000 clinical laboratories that provide testing and 
services in the United States (Wolcott et al., 2008). The consolidation of these 
laboratories is under one statute, the Clinical Laboratory Improvement Amendments 
(CLIA) of 1988 that establishes standards for record maintenance and proficiency testing 
for all laboratories (Berger, 1999). Clinical laboratories play a vital role in the healthcare 
system and perform numerous functions such as research, clinical care, and a multitude 
of other purposes (Wolcott et al., 2008). Furthermore, the practice of laboratory services 
entails a broader scope of influences beyond the activities in the laboratory. These 
influences include (a) consultations with providers regarding test ordering and result 
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interpretations (b) performance measurements for quality improvement (c) and a growing 
scale of direct interactions with patients and the public regarding test results (Wolcott et 
al, 2008). The future of the laboratory reflects the use of evidence-based medicine and 
clinical practice guidelines as key components of improving the continuity of care for 
patients. Healthcare providers, quality assurance organizations, and insurance payers are 
incorporating these key components as indicators to assess objectively quality, cost, and 
access to care for the individual patient and populations in their geographical footprint. 
Impact of the PPACA on Clinical Laboratory Services 
How will the PPACA provisions affect clinical laboratory Services? Several 
aspects of the laboratory are privy to implications of the PPACA. These provisions within 
the new law aim to promote (a) increased access to laboratory tests (b) provide a better 
quality of test results via an improved total testing process (c) reduce cost per laboratory 
test for the average citizens in the United States (Bandyopadhyay et al., 2013). The 
following are noteworthy effects the PPACA has in the laboratory. 
Control workflow. In 2014, the Congressional Budget Office (CBO) and the Joint 
Committee on Taxation (JCT) estimated that the PPACA would create access for 
approximately 14 million nonelderly people to procure health insurance and 
approximately 30 million in subsequent years, bring an influx in demand for primary care 
(Kasoff & Buescher, 2013). Furthermore, by 2012 through 2060 the U. S. Census Bureau 
projects that the elderly population, age 65 and older, is expected to more than double, 
from 43 million to 92 million (Bennett et al., 2014). The key challenge for laboratories is 
the need to better define and highlight the critical role of appropriate clinical services, in 
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order to manage successfully the influx of newly insured individuals across its continuum 
of care. 
Increased Workload. The increase in the number of individuals who now have 
health insurance will likely increase the workload. The availability of insurance coverage 
offers access to more individuals to pursue routine types of healthcare, including 
laboratory tests that were previously inaccessible. The workload is likely to promote the 
idea of new diagnostic and prognostic tools to predict better outcomes of treatment while 
expanding the use of genetic markers to target specific pathologies. In addition, the 
increased workload encourages providers to personalize medicine for chronic conditions 
attributed to the rise of the elder population, while improving cost and efficacy in 
healthcare (Bennett et al., 2014). 
Personnel. Personnel shortages are of concern as the PPACA takes effect. As 
workload increases in clinical laboratories, so will the need to increase personnel to cover 
the growth. Nevertheless, over the last few decades, personnel numbers in the laboratory 
have gradually declined. This decline is due to the closure of numerous medical 
laboratory programs, and the retiring of senior laboratory personnel with numerous years 
of experience (Cearlock, 2012). To ameliorate the shortages, the profession must prepare 
to graduate more students from current programs, open new programs to boost numbers, 
and implement automation systems as a solution to accommodate the deficit. Equally, 
laboratories are likely to pursue other initiatives such as investing in educational 
opportunities (e.g. continuing education program, professional society membership, and 
presenting publications) to improve personnel competency (Otto, 2012). Likewise, 
laboratories are devoted to ensuring personnel are afforded the opportunity to earn 
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advanced degrees as a method of improving laboratory and provider relationship (e.g. 
consultation support of test results) to improve continuity of care for patients regarding 
the PPACA (Otto, 2012).  
Reimbursement. Reimbursement rates for Medicare patients are of importance for 
laboratories. Medicare reimbursements are only at 75% of the levels they were in the 
1980s for the Clinical Laboratory Fees Schedule. This is due to annually adjusting the 
consumer price index and the effects of sequestration cuts proposed by congress 
(Panning, 2014a). In addition, the elimination of the fee schedule updates for five years, 
and the reduction of the fee schedule has forced laboratories to develop practices that are 
more efficient. Consequently, since private insurance emulates Medicare practices, their 
reimbursements rates will be lower as well. These lower rates will require laboratories to 
be more efficient in seeking ways to improve quality and remove unnecessary fees from 
the healthcare system in order to remain viable (Futrell, 2013). There are provisions 
within the PPACA that encourage the reduction of spending while obtaining more value 
for the money spent by reducing payment for non-aligned quality target outcomes 
(Dowd, 2013). Value Based Purchasing Healthcare Reform focused on quality outcomes, 
is one initiative that has forced healthcare organizations to put emphasis on quality. The 
primary objective of this system is to promote safer healthcare and to eliminate 
unnecessary administrative and duplication costs (Futrell, 2013).  
Another initiative regarding reimbursement is creating accountable care 
organizations that use bundled payment methods. One example is the Center for 
Medicare and Medicaid Services Bundled Payments for Care Improvement Initiative 
(BPCI) (Giles, 2011). This payment system provides a single payment for healthcare 
 10 
services that patients receive across a range of care. The service is designed to incentivize 
caregivers to improve the quality of care through coordinated efforts across the value 
chain (Graham, 2015). The conceptualization of bundled payment is that one provider 
receives a single payment for all services provided throughout an episode of care; then 
this payment is divided amongst other providers based on the services rendered (Shay & 
Mick, 2013). All parties involved will receive a portion of the payment, therefore sharing 
equal responsibility for the care provided, thus improving efficiency. The intentions of 
bundled payments are to bridge quality gaps in care through effective collaborations and 
coordination of care between hospitals and providers, particularly to prevent or reduce 
readmissions (Shay & Mick, 2013). 
Other initiatives of reimbursement are the 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems (ICD-10). The 
transition from ICD-9 diagnosis and procedure code sets to ICD-10 on October 1, 2014, 
was one of the largest changes to healthcare submission claims (Kasoff & Buescher, 
2013). The ICD-10 contains codes for diseases, signs, and symptoms, abnormal findings, 
complaints, and external causes of injury. A successful transition for laboratories to this 
new system will help limit rejected claims and subsequently improve cash flow (Kasoff 
& Buescher, 2013). 
Comparative Effectiveness Research. The statute emphasizes comparative 
effectiveness research (CER), an evidence-based approach to help healthcare 
professionals evaluate what tests are most appropriate for specific health conditions, 
subpopulations, and to evaluate treatment options (Lelflar, 2013). The inclusion of CER 
is important to address the problem of excessive practice variation, for the treatment of 
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identical conditions. These variations of treatment seem to exist due to the lack of 
evidence-based medicine that proclaims to produce a superior treatment over an 
alternative method (Agency for Healthcare Research and Quality [AHRQ], 2012). To 
correct the problem, CER postulates a path to publicize on a national level evidence of 
best-claimed practices for a particular condition. Conversely, there has been opposition 
from providers that all patients are different and a one-size fits all approach, is not 
conducive to best practice in the field of medicine (Lelflar, 2013). Nevertheless, CER is 
an important new initiative regarding the new statute; aimed at reducing cost and 
improving patient outcomes. 
Electronic Health Records (EHR). The implementation of electronic health 
records is suggested as a powerful tool to prevent duplication efforts of testing when 
patients change healthcare or/and insurance providers (Lupino, 2015). This electronic 
disruptor has the potential to reduce cost and increase quality by avoiding unnecessary 
repeat administrative procedures and test procedures. Electronic Health Records also 
provide access to physicians, allowing continuity of care for patients throughout their full 
spectrum of treatment from one institution to another (Bandyopadhyay et al., 2013). 
Furthermore, institutions are investing in EHR to assist personnel with the projected 
increase of high throughput and complex test results.  
The U.S. government has incentivized the implementation of EHR through the 
Informatics Incentive Program by subsidizing billions of dollars to healthcare institutions 
to upgrade their current systems in stage one of a two-stage process (Lupino, 2015). 
Conversely, fewer institutions are applying for stage two due to frustration and minimal 
successes for those institutions who have participated in stage one (Lupino, 2015). The 
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verdict is unclear as to whether EHR is improving healthcare; only the future will reveal 
the effects of EHR interoperability on the continuum of care as more laboratories 
incorporate this practice. 
The Medical Device Tax. The medical device tax will be a huge hurdle for 
laboratories to overcome. On January 1, 2013, the PPACA imposed a 2.3% excise tax on 
the sale and import of medical devices (Kasoff & Buescher, 2013). Laboratories that 
purchase these devices are likely to pay the extra expenses, as suppliers, manufacturers, 
and distributors are likely to pass along the added expenses (Kasoff & Buescher, 2013). 
The U.S. government has plans to use the medical device tax as an initiative to pay 
startup cost for PPACA, but the laboratory community perceives the new tax as another 
expense that exacerbates financial pressure on an already strapped laboratory industry 
(Miles &Weiss, 2011). Currently, the laboratory industry along with bipartisan support in 
congress is fighting to ban this provision because of added economic pressure. If this tax 
is not repealed, the laboratory industry will likely face increased financial hurdles that 
could negatively affect operations.  
Presently, there are several implications brought on by the PPACA that will 
require laboratories to become more productive and cost conscience than ever before. 
These changes appear to be necessary to control health care spending while producing 
better outcomes. However, will the PPACA be the savior to champion this control? There 
are laboratorians who feel that the PPACA is overwhelmed with the new changes of 
reimbursement cost, provisions for accessibility, and benchmarks for quality. However, it 
is important for laboratorians to focus on the incentives, new reimbursement models, and 
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prevention programs dedicated to improving the healthcare system, for the betterment of 
all U.S. citizens (Kasoff & Buescher, 2013). 
Purpose of the Study 
The purpose of this study is to design the most theoretical, statistical instrument 
based on the theory of the iron triangle. This study will assess the relationships of access, 
cost, and quality in clinical laboratories post implementation of PPACA. The objectives 
of this study are to: 
1. Confirm that the indicators, technology-Q, patient safety, and personnel 
measure the construct “Quality” as operationalized in this study. 
2. Confirm that the indicators, technology-C, utilization-C, and reimbursement 
measure the construct “Cost” as operationalized in this study. 
3. Confirm that the indicators, reform, utilization-A, and fee measure the 
construct “Access” together with the latent variables, Cost, and Quality as 
operationalized in this study. 
4. Design a measurement instrument with the intent of producing a parsimonious 
structure without sacrificing the comprehensiveness of the assessment of 
PPACA on clinical laboratory services. 
5. Hypothesize (a priori) that the constructs relationships in the predicted model 
resemble the constructs relationships in the observed data set. 
Expectations 
The construct, independent variable “Cost”, will be operationalized by measuring 
questions from the subscales of technology-C, utilization-C, and reimbursement with 
expectations of a decreasing relationship to the construct independent variable “Access”. 
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The construct independent variable “Quality” will be operationalized by measuring 
questions from the subscales of technology-Q, patient safety, and personnel with 
expectations of an increasing relationship with the independent construct variable 
“Access”. The construct independent variable “Access” will be operationalized by 
measuring questions from the subscales of utilization-A, reform, and fee; and from the 
independent construct variables of Cost and Quality. The outcomes from these 
relationships are expected to result in an increase in Access and Quality; while producing 
a decreasing relationship with Cost for patients in the healthcare value chain. 
Assumptions 
Assumptions of the PPACA related to this study presume that all laboratories are 
affiliated with CLIA. Other assumptions are as follows: 
1. Clinical laboratories adjusted their business practices regarding 
implementation of the PPACA. 
2. The PPACA’s individual mandate creates a greater demand for services. Most 
states are expanding their Medicaid programs, and health care exchanges are 
set up to help individuals purchase health insurance as a requirement of the 
PPACA. 
3. The exemption of pre-existing conditions and subsidies for individuals and 
families that fall within a certain range of the federal poverty line provides an 
increase in laboratory services. 
4. Participants with knowledge regarding quality, access, and cost in the 
laboratory will answer the survey honestly. 
 15 
5. The survey items are sufficient indicators of the constructs post 
implementation of the PPACA. 
6. The sample size will be sufficient to evaluate the impact of quality, cost, and 
access of the PPACA is having on clinical laboratory services. 
Limitations 
1. The sample size is collected from selected CLIA laboratory managers from 
numerous states; therefore, the results may not represent other laboratory 
entities throughout the United States. As a result, objectification cannot be 
applied to every laboratory throughout the United States.  
2. Some participants’ responses on the survey may be biased to the effects of 
PPACA, depending on their ideology, partisanship, and culture. 
3. The survey items focus on the three constructs (quality, access, and cost) of 
the iron triangle in regards to clinical laboratories efficacy post 
implementation of PPACA. However, there are possibly other indicators or 
variables available to assess efficacy in clinical laboratories. 
4. Time is a limiting factor. Perhaps, if more time were available to conduct a 
profound number of subjects regarding the three constructs, the data from the 
study would be more informative and objective. 
Definitions and Terms 
Access: Access to health care describes the relationship of availability and use of 
insurance for healthcare when needed. 
Bundled Payment: The CMS Bundled Payments for Care Improvement Initiative 
provides a single payment for services that patients receive across a continuum of care. 
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Cost: Cost is associated with the affordability of healthcare for patients and 
payers at a given rate. 
Hospital laboratories: Chief provider of laboratory services for their inpatient 
population as well as outpatient population receiving care from physicians who are 
affiliated with the hospital. 
Physician Office Laboratories: A diagnostic laboratory in a physician’s office 
with an abbreviated menu of tests that can be performed while the patient is in the office, 
so the physician can better manage the patient. 
Quality: Quality addresses the value and benefits of the outcomes received from 
healthcare provided. 
10th revision of the International Statistical Classification of Diseases and 
Related Health Problems (ICD): A medical classification list by the World Health 
Organization (WHO). It contains codes for diseases, signs, and symptoms, abnormal 
findings, complaints, social circumstances, and external causes of injury (Kasoff & 
Buescher, 2013). 
Clinical Laboratory: Testing services and associated practices for the assessment, 
diagnosis, treatment, management, or prevention of health-related conditions utilized in 
making patient care decisions and improving public health. 
Patient Protection and Affordable Care Act (PPACA): Legislation, commonly 
referred to, as “Obamacare,” enacted by the U.S. Senate and House of Representatives in 
2010. This act reformed health care for all Americans (H.R. 3590). 
Reimbursement: To make repayment for services and goods rendered to 
individuals for health care issues. 
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Technology: Automation of new testing methods and processes coupled with 
sophisticated laboratory information systems to improve efficiency. 
Hypothesis 
Ho: There is a non-significant difference in the variables interrelationships 
between the predicted model and the observed model data set; therefore, this survey will 
serve as a plausible instrument to assess the PPACA as a disrupter to the iron triangle of 
health care. 
H1: There is a significant difference in the variables interrelationships between the 
predicted model and the observed model data set; therefore, this survey will not serve as a 
plausible instrument to assess the PPACA as a disrupter to the iron triangle of health care. 
Research Questions  
1. Are the variables technology-Q, patient safety, and personnel appropriately 
measuring the latent variable “quality” as a disrupter to the iron triangle? 
2. Are the variables technology-C, utilization-C, and reimbursement 
appropriately measuring the latent variable “cost” as a disrupter to the iron 
triangle? 
3. Are the variables technology reform, utilization-A, and fee appropriately 
measuring the latent variable “access” as a disrupter to the iron triangle? 
4. Is the goodness of fit between the predicted model and the observed data 
similar enough to explain the hypothesized relationships of the PPACA as a 
disrupter to the iron triangle? 
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CHAPTER II – LITERATURE REVIEW 
A comprehensive review of the literature was conducted with the impetus of 
determining the progression of the U.S. healthcare system and its effect on clinical 
laboratories. A broad review of journal articles, books, and report papers was conducted 
to gain insight as to the indicators used to measure healthcare cost, quality, and access in 
the laboratory. The following literature review provided a framework for readers to put in 
context the definition of cost, quality, and access as it pertains to the laboratory post the 
PPACA.  
The literature search for background information was conducted using The 
University of Southern Mississippi Cook Library collections of electronic journals. 
Although the search was not exhaustive, it was limited by intent. PubMed, EBSCO host 
and Medline were used to define the database search parameters. The original phrase 
search was done for the phrase “iron triangle of health care for clinical laboratories”, but 
was very limited due to the lack of studies conducted on the topic. Additionally, other 
search words such as access, cost, and quality were used to obtain articles that were 
independent studies for each of the words. Other searches using the keywords: 
Confirmatory factor analysis and Structural equation modeling helped to streamline 
articles further, in order to scale the information down to a manageable size for analysis. 
Background of the Study 
The issue of healthcare insurance reform in the United States has been the subject 
of political debate since the early part of the 20th century. A brief history of healthcare 
reform is as follows:  
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1. During the progressive era of Theodore Roosevelt from 1901-1909, he 
pledged a campaign on social insurance for the sick, poor, irregular 
employment, and old age, because he believed that a country is incapable of 
being strong with a nation of sick and poor people (Palmer, 1999). Most of 
these initiatives took place outside the government; needless-to-say 
Roosevelt’s conservative successors postponed the advancement of social 
welfare for the public for about twenty years. 
2. During Franklin D. Roosevelt’s tenure, from 1933-1945 healthcare insurance 
was considered in the Social Security Bill of 1935 and the Wagner Bill 
National Health Act of 1939 (Igel, 2008). However, both were failed attempts 
for healthcare reform due to threats of impending comprehensive social 
security legislation, and the resurgence of conservative partisanship against 
universal healthcare respectively. 
3. From 1945-1953 Truman became president and health care issues finally 
moved to the forefront of national politics under the Fair Deal Campaign 
(Geselbracht, 1999). However, in 1949 strong opposition opposed the deal.  
4. In 1965, President Lyndon B. Johnson created Medicare and Medicaid the 
first social insurance program administrated by the United States government 
(Palmer, 1999). Nevertheless, this program only provided health insurance 
coverage, for people who were 65 and older, or for individuals who met 
special criteria. 
5. In 1972, President Nixon signed the Social Security Amendments of 1972 
extending Medicare to those under 65 who were severely disabled for over 
 20 
two years and introduced health care maintenance organizations (Palmer, 
1999). 
6. In 1985, President Regan expanded Medicare, through the Consolidated 
Omnibus Budget Reconciliation Act (COBRA) giving some employees the 
ability to continue health insurance coverage after leaving employment 
(Palmer, 1999). 
7. George H. W. Bush repealed the Regan Medicare expansion and proposed the 
private insurance model and incentives to improve outcomes and reduce costs. 
In 1993, President Clinton proposed universal health care for all Americans 
through the initiative of the Health Security Act (Palmer, 1999). Due to rising 
opposition, the act failed to gain traction in congress and it was dismissed. 
8. In 2003, President George W. Bush created the Prescription Drug Benefit for 
Medicare Part D, which included a prescription drug plan for the elderly and 
disabled Americans (Centers for Medicare & Medicaid Services [CMS], 
2006). This act was the largest overhaul of Medicare in the public healthcare 
program’s 38-year history; however, it did not become universal healthcare 
for all Americans. 
9. After 100 years of efforts to create and pass universal health care through 
congress, President Obama finally, succeeded in making it possible through 
The Patient Protection and Affordable Care Act of 2010 (Panning, 2014b). 
Prior to the PPACA, the health care system was marked by fragmented 
healthcare delivery that resulted in poor quality patient experiences, inefficient 
operations, and substandard clinical outcomes (Panning, 2012). 
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The Patient Protection Affordable Care Act objective is to provide access to the 
health care system for more individuals under the age of 65, and individuals at or under 
the federal poverty line of 133%. Subsidies through Medicare/Medicaid will be granted 
to low-income individuals and children across all states to assistance with the transition 
into the system. Advocates for the PPACA suggest a means to improve healthcare access 
without increasing cost and compromising quality is to decrease inefficiencies such as; 
excessive administrative fees, employ the economy of scale model to reduce cost per 
individual, and change the delivery of healthcare from a quantity to a quality-based 
system. In addition, expectations of the PPACA are to realign the healthcare system to 
incentivize and reward preventative practices that improve the efficacy of care for 
American citizens. 
Opponents of the PPACA postulate, the statute did nothing to improve the 
healthcare system. According to Carroll (2012), the new statute does conform to the 
theory of the iron triangle; therefore, by increasing access one will inevitably increase the 
cost or decrease the quality. Carroll (2012) also believes that PPACA will cost over $900 
billion to fund all of its provisions. While there are suggestions of tax reliefs and 
spending cuts to cover these new expenses, opposition leaders are curious as to whether 
or not these breaks actually exist (Carroll, 2012). The ultimate question is will the 
PPACA, be an effective disrupter to the iron triangle? If so, as a disrupter, the biggest 
impacts for the laboratory will be to improve the quality of testing at an economical price, 
while managing the increased workload due to granting healthcare accessibility to the 
individualized American citizen made possible by PPACA.  
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Theoretical Framework 
The theoretical framework for this study is the iron triangle of health care, first 
proposed by William Kissick in 1994. The word iron represents the competition between 
the three vertices (access, cost, and quality) of the triangle (Lehman, 2015). Access to 
health care describes the relationship of availability of healthcare when needed. Cost is 
associated with the affordability of healthcare for patients and payers at a given rate. 
Quality addresses the value and benefits of the outcomes received from healthcare 
provided.  
The conceptualization of the theory is that healthcare is a tightly linked, self-
equilibrating system of three constructs: cost, quality, and access as seen in Figure 1. 
 
 
 
 
Figure 1. Iron Triangle of Healthcare 
Illustration of the three vertices (constructs) of the iron triangle of health care based on the theory of Williams Kissick, 1994. 
Healthcare is measured on the three constructs access, cost, and quality, and shares equilibrium between the constructs totaling 180 
degrees.  
As an increase occurs in one or two of the constructs, this inevitably results in an 
effect on the other construct in maintaining equilibrium within the model. For example, if 
access is increased then cost will be increased, and or quality will be decreased to 
maintain the equilibrium, excluding adding other factors in the existing model (see Figure 
2). 
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Figure 2. Access Increased on the Iron Triangle 
Illustration of the iron triangle, as access increase to 90 degrees, one or both of the other constructs (cost and quality) must decrease to 
maintain 180 degrees in the triangle.  
Alternatively, if the quality of care is increased then access and or cost must 
decrease to maintain equilibrium if no other factors are included in the model (see Figure 
3). 
 
 
 
 
Figure 3. Quality Increased on the Iron Triangle 
Illustration of the iron triangle, as quality increases to 90 degrees, one or both of the other constructs (access and cost) must decrease 
to maintain 180 degrees in the triangle.  
For this study, Figure 4 will be of importance regarding increasing access with 
aspirations to increase quality while decreasing cost (Russell, 2012). If the Patient 
Protection and Affordable Care Act performs as predicted, then the iron triangle of health 
care for the laboratory will resemble that is seen Figure 4. 
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Figure 4. The Effect of PPACA 
The Patient Protection Affordable Care Act as a disrupter to the iron triangle of health care on laboratories; the triangle presents with 
an increase in access and quality and a decrease in cost associated with healthcare in the laboratory.  
To date, there has been limited research conducted on the conceptualization of the 
iron triangle regarding clinical laboratories post implementation of the PPACA’s 
provisions. However, there are reports that focus on the three constructs (cost, access, and 
quality) independently of each other, providing useful information as a solid foundation 
for this study. The following paragraphs will discuss how the indicator variables were 
determined from the previous literature regarding the three constructs. 
Healthcare Access in the Laboratory  
Access is concerned with providing individuals the accessibility and availability, 
to receive healthcare with appropriate resources in order to preserve and/or improve their 
health (Guillford et al., 2002). If services are available and there is adequate supply to 
support the service, then individuals have the opportunity to obtain healthcare. The logic 
seems simple; however, the term access is complex when referring to healthcare, which is 
viewable through different lenses. More broadly, barriers such as finance, organization 
structure, culture can create inequitable circumstances that influence healthcare 
accessibility. Therefore, for this study, access will be observed from a broader lens to 
gain an understanding of what it means to have healthcare access, using the Institute of 
Medicine Model of Access. From there, the focus will be narrowed to the category of 
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healthcare services within the model to clarify further the viewpoint of access to 
laboratory services post implementation of the PPACA. 
The Institute of Medicine (IOM) Model of Access 
The Institute of Medicine Model (IOM) of Access was developed in the 1990s, to 
provide specifically a structure of timely care to achieve optimal outcomes and close gaps 
in health care (Institute of Medicine [IOM], 1993). The conceptual framework of the 
IOM model is to monitor the quality of healthcare services by assessing barriers and 
utilization to the outcomes of care received (see Figure 5). Overcoming the barriers 
within the IOM model is the first step in gaining access to the system. Provisions in the 
PPACA like the individual mandate, open market to purchase healthcare insurance, and 
Medicaid expansions in states are important factors in overcoming these barriers. Use of 
services and mediators are the next step in the model that accounts for provider 
availability, procedures, and efficacy of the treatment given. Provisions within the 
PPACA such as new testing methodologies, education of staff, and quality versus 
quantity of test performance are important factors to ensure appropriate treatment. 
Finally, the outcome step of the IOM model of access assesses the performance of the 
barriers and use of services to predict the status of individual’s health (outcome). 
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Figure 5. The Institute of Medicine Model of Access 
The dynamics of participation in the personal healthcare system: Namely, access problems are created when barriers cause underuse 
of services, which in turn leads to poor outcomes. Adapted from Institute of Medicine (US) Committee on Monitoring Access to 
Personal Health Care Services, by M. Millman,1993;  Courtesy of the National Academies Press, Washington, D.C. p. 35. 
Within this model, the categories of use of healthcare services and mediators 
(utilization) are important indicators for assessing clinical laboratories (Karikari-Martin, 
2010). One way to realize the effect of the PPACA on health services within the clinical 
laboratory is to develop indicators that assess the frequency of visits, and the number of 
laboratory tests performed over time (Millman, 1993). Identifying the correct indicators 
within the use of services and mediators is an important function of this study. 
Operationalization of Access in the Laboratory 
The IOM model of access was instrumental in identifying indicators to assess 
accurately the construct of access as it relates to healthcare in the laboratory. The 
indicators assembled from the model of access are reform, fee, and utilization (Otto, 
2012). These indicators are posited to be the most appropriate indicators to assess access 
from the consensus of laboratory professionals. The operationalization of these indicators 
regarding access in the laboratory is as follows: 
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Reform (Screening test). Access to the laboratory for this study refers to the 
variables of increased screening, and diagnostic tests for patients such as Hepatitis B, 
Human Immunodeficiency virus, complete blood count and other tests. The number of 
tests performed and/or new testing platforms created provides an indication as to whether 
or not reform will be a valid indicator of access. In addition, screening and diagnostic 
tests in health plans at no or reduced cost to the consumer will result in better outcomes 
for the patient and provider. Furthermore, long-term costs should decrease as the severity 
and incidence of disease decreases. Evidence currently supports the value of a number of 
laboratory screening tests to accommodate the increase in the number of individuals who 
will have health insurance. 
Direct access to laboratory testing is another important provision of reform to 
healthcare. It allows patients to receive test results directly from the laboratory 
performing the tests, without provider visitation. Direct access increases the availability 
and use of preventive testing, as well reduce provider cost by exempting office visits 
(Health and Human Services [HHS], 2014). In order to protect the public, guidelines 
must be inclusive regarding direct access to ensure testing is appropriate, testing is 
performed in certified laboratories, results are understandable, and follow-up visits are 
available if needed (HHS, 2014). The thought behind direct access testing is that it 
increases patient access, allows the patients to be more involved in their care, and it 
advocates that healthcare is more of a preventative type of service. 
Fee (Healthcare Cost). The decrease in individualized healthcare cost and the 
reimbursement rates that influence financial capability of laboratories are the indicators 
for fee. The individual mandate requires all individuals to have insurance, which helps 
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promote the economy of scale, therefore decreasing cost per individual and increasing 
access for the public to obtain healthcare (IRS, 2014). The assumption is that younger 
healthier people will subsidize the care for the elderly and less healthy individuals 
(Panning, 2012). The concept is that younger people pay it forward for the older 
generation. As the younger generation progresses in age, subsequent generations will pay 
it forward to cover their health care premiums in hopes of sustaining healthcare payments 
infinite. 
Reimbursement rates are vital to how laboratories perform after the 
implementation of the PPACA. Laboratories will have to increase the throughput of 
laboratory tests because of the expected lower reimbursement rates. Supporters of the 
PPACA believed that laboratories might lose money as an entity at the initiation of the 
change, but the system as a whole will benefit from faster, better treatment of patients as 
well as increased patient and physician satisfaction (Lehman, 2015). The objectives of 
clinical laboratories are to address fee-for-service reimbursement models and employ 
quality-based goals that focus on value rather than volume of comprehensive healthcare 
(Futrell, 2013). As a result, the reimbursement methods are projected to reduce health 
care cost for the individual patient and create financial stability for laboratories. 
Utilization-A (New testing). The PPACA will place numerous demands on the 
laboratory in the form of an aging population, a growing prevalence of chronic diseases, 
and increased utilization due to expanded access to healthcare. The availability of new 
testing is fundamental in the laboratory community in controlling these demands. New 
testing techniques to screen and diagnose conditions are often available before effective 
innovative treatment is accessible (Bandyopadhyay et al., 2008). For the past few 
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decades, the clinical laboratory has been characterized by ongoing rapid and dramatic 
innovations coupled with remarkable growth in range and complexity of available tests 
and services. Advances in equipment and continued miniaturization of testing equipment 
are unique ways of expanding the test menu of laboratories (Bennett et al., 2013). 
Miniaturization of assay technology offers more high-volume testing. This type of 
technology is more efficient with less administrative and variable expenses to the 
laboratory. This new platform of testing is expected to accommodate the increased testing 
workload that is associated with the increase in access of the population.  
Healthcare Quality in the Laboratory 
Healthcare must be safe, well-coordinated, evidence-based, responsive to patient 
needs, and continuously improving. The Patient Protection Affordable Care Act 
established the National Strategy for Quality Improvement in Health Care to guide the 
efforts to increase access to high quality and affordable healthcare (Agency for 
Healthcare Research and Quality [AHRQ] 2012). The strategy of the National Strategy 
for Quality is to focus on eliminating the variability of care from patient to patient, reduce 
the use of unnecessary care, and use data-driven decisions to improve care. The goal of 
the National Strategy for Quality is to ensure “that each patient receives the right care, at 
the right time, in the right setting every time (Shahangian & Snyder, 2009, p 420).” To 
achieve this quality initiative for clinical laboratories, the Institute of Medicine Model of 
Quality is used in this study. 
Institute of Medicine Model of Quality 
Although America has the highest cost per capita regarding healthcare, there is 
evidence that suggests a disparity between standards of care and expected outcomes 
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(quality). At one point, the stewards of healthcare became content with its quality, until 
the Institute of Medicine (IOM) issued “To Err is Human:  Building a Safer Health 
System” report in 1999, and “Crossing the Chiasm: A New Health System for the 21st 
Century” in 2001 (IOM, 2001). Within these reports, frequently health care either harmed 
or did not provide the expected benefits to patients. To address the issue of quality, the 
2001 IOM report suggested filling the gaps between the standard of care and expected 
outcomes (IOM, 2001). The core concepts developed from the report were centered on 
six aims for improvement, which are “patient safety that avoids injury, effective services 
that provide benefit, patient-centered care designed for the individual patient, timely care, 
efficient care to avoid waste of resources, and equitable healthcare that does not vary 
from individual to individual (IOM, 2001, p 5).” It is well recognized that many medical 
services provided each year are unnecessary or of limited clinical value to patients. It is 
important for laboratorians to understand these unwarranted practices, and then use the 
knowledge gained to make improvements on the quality and delivery of healthcare 
(Futrell, 2013). The IOM model of quality was instrumental in identifying indicators to 
assess accurately the construct of quality as it relates to improving healthcare in the 
laboratory. See Figure 6 below to examine the IOM model of quality. 
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Figure 6. The Institute of Medicine on Quality, 2001 
Figure portrays the dynamic role of laboratory medicine in the health care system. The premise of this diagram has is that value can be 
expressed in terms of achieving the six aims posed by the IOM. Adapted from 2001, P. 21 Laboratory Medicine:  A National Status 
Report, Courtesy of the National Academics Press, Washington, D.C.  
Operationalization of Quality in the Laboratory  
According to many laboratory clinicians and providers, the quality of the 
laboratory is determined from the standpoint of three measurable indicators that 
encompass all six concepts of the quality IOM model. These measurable indicators are 
technology-Q, patient safety, and personnel are operationalized as follows (Otto, 2012): 
Technology-Q. Automation addresses the need to incorporate automation 
instrumentation into the laboratory for performing molecular testing and other complex 
methodologies. The use of molecular automation testing reduces human errors and helps 
to avoid over test-utilization during total testing processing and interpretation of complex 
laboratory testing (Bennett et al., 2013). Furthermore, automation provides better 
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management of reflex testing and allows a seamless transmission of results that promotes 
better patient care. According to Joseph and Kip (2016), automation offered by molecular 
testing is valued to existing health data, through individualized medicine. The aim of 
multiplexed molecular testing is the detection of multiple causative agents or 
abnormalities from a single clinical specimen; therefore reducing unwarranted 
duplication efforts in collecting the specimen. Conversely, single-gene automation testing 
attempts to find the specific genetic abnormality, guiding personalized therapeutics for 
better-individualized care (Futrell, 2013). Balancing these divergent goals is crucial in 
developing an efficient laboratory diagnostic workflow. While total laboratory 
automation of testing processes may not be possible for all medical laboratories due to 
high startup cost, many have automated some portion of their operations to improve 
quality (Futrell, 2013). The trend for automation testing continues to grow in the 
laboratory as a method of improving quality across the continuum of healthcare in a 
variety of ways. From offering flexibility and specificity in allowing laboratories to 
broaden or narrow the range of assays, to the level of sophistication that can assist in the 
pre-analytical, analytical, and post-analytical phase of testing in the laboratory 
automation seems to be the future. 
Patient Safety. Effective studies focus on patient-centered care; ensuring 
laboratory tests ordered by physicians are beneficial and necessary for the patient. A 
meta-analysis of 108 studies conducting by Cadogan, Browne, Bradley, and Cahill 
(2015), involving 1.6 million results of the most commonly ordered laboratory tests in 
medicine found that on average, 30 % of all tests are likely to be unnecessary. The 
implementation of PPACA encourages patient-centered quality, meaning that tests 
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requested by the physician are trustworthy, timely, and beneficial for the patient 
(efficacy). The idea for patient safety in the clinical laboratory is to ensure that the 
selection of “the right test, for the right patient, at the right time (Morrison, Otto & 
Golemboski, 2013, p 201)”. Delivery of test results in a timely fashion with accurate 
interpretation and valid patient-oriented outcomes is the primary goal of patient safety. 
Personnel. The PPACA emphasizes the need for workforce development 
strategies, to ensure an adequate supply of qualified professionals who are able to meet 
the changing demands of the healthcare system. Over the last few decades, there has been 
a decline in medical laboratory personnel across all ranges of educational levels (Castillo, 
2000). This decline is attributed to the supply side, which is retention, retirement, and 
recruitment; and the demand side, which are regulatory reforms, population 
demographics, and advancements in medicine (Bennett et al., 2014). According to the 
National Accrediting Agency for Clinical Laboratory Sciences (NAACLS), in the past 15 
years closure of clinical laboratory schools has reduced the number of laboratorians that 
are trained annually (Cearlock, 2012). Numbers show individuals graduating from 
laboratory programs have declined roughly 14% since 1994 to the present, and the 
number of laboratory training programs has decreased almost 25% (Cearlock, 2012). 
Program closures have been the result of a multitude of factors, including declining 
enrollment and cost. For many hospital-based programs, the implementation of the 
Medicare Prospective Payment Systems changed the hospital payment structure to a 
degree that medical laboratories, once a source of revenue became cost centers (Bennett 
et al., 2014). The transition to cost centers led to a decline in training programs, which 
has a profound effect on the number of clinical laboratory scientists graduating annually. 
 34 
In addition, the number of experienced laboratory professionals that has reached 
retirement age has ignited greater concerns for the profession (Bennett et al., 2014).  
To compensate for a declining workforce, the profession offers new opportunities 
such as; advances in laboratory information management that experienced laboratory 
professionals with an affinity for informatics are likely to pursue. Other efforts to address 
personnel issues result in many laboratories offering educational opportunities, in the 
form of advanced degrees to promote better physician-laboratorian relationships, and 
professional development opportunities such as publication of journals, and the 
attendance of conferences to improve competence (Passiment, 2006). In the future, the 
aim of the medical laboratory community is to recruit young people into the profession, 
retain seasoned professionals into retirement age, and engage young professionals in the 
workplace to enhance the profession. 
Healthcare Cost in the Laboratory 
The cost of healthcare should be affordable to all individuals. Individuals must be 
able to manage the expenses of care and the cost of healthcare provided. While the 
United States has the best-trained medical personnel and the highest level of technology, 
the reality is that when compared to all industrialized countries, our cost is the highest 
and our quality and outcomes are near the lowest (Truman, 2013). Some scholars believe 
escalating costs are contributions of economic pressures that health care in the United 
States has placed upon employers’ bottom line in trying to compete in the global market. 
The belief is that healthcare for employees significantly adds to the cost of goods and 
services and are disproportion with the rest of the world (Panning, 2014b).  
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To curb cost several options have been proposed on reimbursement methods in 
order to make the healthcare system less taxing on the economy. For example, 
Accountable Care Organizations (ACOs) link reimbursement rates to the quality of 
service rendered by the provider. The objective of ACOs is to ensure providers are using 
informed evidence-based medicine that prevents unnecessary services to the patient; thus 
decreasing cost but simultaneously increasing access and quality to the population. ACOs 
may use different payment models, such as capitation method, fee-for-service method, or 
the prospective method, in an effort to improve health and reduce cost (Panning, 2012). 
Other models include the Patient-Centered Medical Home (PCMH) model and the 
Health Maintenance Organization (HMO) structure. The patient-centered medical home 
(PCMH) initiative is similar to ACOs in that it emphasizes the physician responsibilities 
across the continuum of healthcare. However, ACOs differ from PCMH by providing 
incentives based on the performance and the responsibility of physicians regarding 
coordination of care (Panning, 2012). 
The Health Maintenance Organization (HMO) structure is another reimbursement 
method that has been around for decades. HMO differs from ACOs in that its payment 
method is mainly associated with capitation while the ACO uses a variety of methods 
such as bundled payment, the fee-for-services payment, and prospective payment coupled 
with incentives to oversee quality and cost of healthcare (Panning, 2012). 
All of these models are similar with slight differences in the form of payment 
procedures (capitation versus bundled-payments), explicit incentives offers, and the 
responsibility for care coordination. The aims of these models are to reduce costs, while 
improving quality and efficiency, through an innovative approach to delivering 
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comprehensive patient-centered preventive and primary care. For this study, information 
was combined with all three models to capture the best practices in decreasing cost while 
maintaining or increasing quality and access in transforming the healthcare system.  
Operationalization of Cost in the Laboratory 
The indicators selected to assess cost in the laboratory are technology-C, 
utilization-C and reimbursement (Otto, 2012). These variables were chosen from the 
perspective of laboratory managers, national reports, and the aforementioned three 
models (HMO, ACO, and PCMH) as the most appropriate indicators to assess cost as it 
pertains to the clinical laboratory. 
Technology-C (Genetic Testing). Many new molecular diagnostic techniques and 
laboratory tests have been introduced through research and the pathology of diseases. 
Rapid advances in the areas at the molecular-level and genetic testing are dramatically 
changing the clinical landscape. Genetic testing is extremely efficient, using micro-
samples to produce life-altering influence; therefore, it is important that these tests be 
subjected to appropriate regulatory compliance (Wolcott et al., 2008). These genetic tests 
can be used to diagnose disease and or predict maladies in the future; they are also used 
to pinpoint anomalies and identify genetic traits in the fetus. Currently, over 1400 
diseases can be identified using genetic testing, and the genetic repository has over 7,000 
orderable tests available (CDC, 2014). Genetic testing is becoming an increasingly 
important component of healthcare delivery and the number and availability of these new 
tests continue to grow. The support of information technology has revolutionized the way 
molecular and genetic test results are ordered and received. The American Recovery and 
Reinvestment Act of 2009 (ARRA) has made the interoperability of health information 
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systems a priority; in an effort to streamline data, reduce error, and increase workflow to 
encourage better outcomes for patients and providers regarding genetic testing (Bennett 
et al., 2014). 
Utilization-C. Utilization is assessed by the variables aging population and test 
menu expansion. According to U.S. Census Bureau projections, the 65 and older age 
group will more than double, from 43.1 million to 92.0 million between the years of 
2012-2060 (Bennett et al, 2014). This older population is projected to represent one-fifth 
of the U.S. population making it a priority for healthcare (Bennett et al, 2014). The 
demographic age shift of the population will be profound for the U.S. healthcare system 
as the elderly are more likely to use healthcare services at a more frequent rate than 
younger people are.  As a result, chronic diseases will likely increase as elderly people 
are living longer and are more apt to exhibiting diseases that are chronic in nature. 
In addition, estimates from the Congressional Budget Office (CBO) and the Joint 
Committee on Taxation (JCT) indicate that the PPACA will reduce the number of 
nonelderly people without health insurance coverage by 49 million, bringing a surge in 
the demand for primary care (Congressional Budget Office [CBO], 2013). Major changes 
are also anticipated in the delivery of healthcare services as the demographic shifts. The 
growing menu of available clinical tests will have a huge impact on providing quality and 
efficient services to these patients. 
Reimbursement. Indicator variables used to assess the subcategory of 
reimbursement in this study are copayment and bundled payment. The majority of 
Medicare services provided to patients has some form of copayment that involves a 
percentage of the services rendered are paid for by the patient and the remaining cost paid 
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by the insurer. This sharing of cost reduces Medicare’s overall burden of financial 
responsibility. In contrast to laboratory services, there is no co-payment fee, a decision 
that became effective in 1984 when the fee schedule was implemented (Panning, 2014a). 
Recently, there have been talks of considering a copayment for laboratory services. 
However, since laboratory tests are relatively low in price, oppositions to this idea 
includes that it would reduce reimbursement rates. In addition, there is concern that it 
would add more administrative cost to the laboratory to collect a single payment directly 
from patients (Panning, 2014b). 
Bundled payments bring new initiatives that parallel the actions of what the 
PPACA is trying to do with healthcare. The bundled payment method has a triple aim: 
improve healthcare, improve quality and reduce cost per capita. The principal of the 
bundled payment is to move healthcare away from quantity services to more of a quality-
based outcome model (Graham, 2015). It is believed that this principle can be achieved 
by aligning the services and goals of the patients, providers, and all parties involved to 
improve quality based on data-driven decisions. The ultimate goal of the bundled 
payment model is to reduce variability and cost in healthcare. 
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CHAPTER III  - METHOD 
The project is a quantitative study that collected data from willing participants 
(clinical laboratories managers) throughout the United States, and then their responses 
analyzed using structural equation modeling (SEM). The collection of data consisted of 
using a survey to assess the constructs of access, cost, and quality of clinical laboratories 
post implementation of PPACA.  
The target population is 250,000 CLIA Laboratory Managers throughout all 50 
states. The population sample is approximately 160 hospital-based laboratories, 
physician-based laboratories, and reference laboratories. The sample size, the sample 
power, and the sample precision are based on using SEM to analyze data. With SEM, the 
larger the data set the more reliable the data analyses and validation of the model. 
According to Myers, Gamst, and Guarino (2013), a minimum of 10-20 items per 
indicator variable (endogenous) are needed (Chapter 16, p 878) for a SEM data set. For 
this study, nine (9) indicator variables are used, with a minimum of 15 items per indicator 
variable. Multiplying the nine indicators (endogenous) variables with 15 items per 
variable will produce a minimum of 135 participants needed for the study.  
Solicitation of the participants was by e-mails to obtain permission for the study. 
Participants at different hospitals and clinics affiliated throughout the states were 
recruited via an electronic information memorandum. The memorandum described the 
study and its ultimate purpose. In addition, the introduction of the survey disclosed that 
all participants need to be 18 years or older to participate. Confirmation of individuals 
who were 18 years or older were verified by the participants’ continuation to conduct the 
survey without the input of others.  
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The survey was sent to all clinical laboratory managers and directors via email, 
providing a unique survey link that tracked each participant’s survey responses. 
Participants were able to complete a portion of the survey and return later to finish the 
rest at a future date. If a participant preferred a hard copy, the survey was sent to his/her 
preferred mailing address with an enclosed stamp envelope for convenience to return the 
survey. If the participant preferred the survey to be conducted by telephone, then a time 
was arranged at his or her convenience to conduct the survey. 
Table 1 shows the relationship between research questions and survey questions 
regarding the constructs Access, Quality, and Cost. Survey questions 1-10 addressed the 
first research question concerning Access. Survey questions 11-20 addressed the second 
research question regarding Quality of health care since the implementation of ACA. 
Survey questions 21-30 addressed the third research question regarding Cost associated 
with changes made in the clinical laboratory to meet the challenges of PPACA. 
  
Relationship Between Research Questions and Survey Questions 
Research Questions Survey Questions 
RQ1: Are the variables technology Reform, 
Utilization-A, and Fee appropriately 
measuring the latent variable “Access” as a 
disrupter to the iron triangle? 
 
1. Your laboratory is likely to increase 
screening tests such as HIV, Hepatitis B, 
and Lipid Profiles etc. 
2. Your laboratory is likely to incorporate 
direct access testing (i.e. patients are able to 
request test results directly from the 
laboratory). 
3. Your laboratory is likely to experience an 
increase in first-time insurance users.  
4. Your laboratory is likely to experience an 
increase in state funding due to Medicaid.   
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Table 1 (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RQ2: Are the variables Technology-Q, 
Patient Safety, and Personnel appropriately 
measuring the latent variable “Quality” as a 
disrupter to the iron triangle? 
 
5. Your laboratory is likely to experience a 
decrease per individual cost for testing.   
6. The impact of reducing reimbursement 
rates are not likely to affect the financial 
viability of your laboratory (i.e. lower rates 
for the clinical laboratory fee schedule, 
sequestration cuts, adjustments to the 
consumer price index etc.).   
7. Your laboratory is likely to experience an 
increase in the prospective payment system 
(i.e. set amount per patient, regardless of the 
amount of care received). 
8. Your laboratory is likely to incorporate a 
wide range of different laboratory tests to 
accommodate the projected increase in the 
elderly population (i.e. 65 and older) 
9. Your laboratory is likely to experience an 
increase in miniaturization of assay methods 
to expand the test menu (i.e. lab-on-a-chip 
and point of care testing). 
10. Your laboratory is likely to experience 
an increase in new testing platforms to 
improve efficiency (i.e. core lab concept). 
11. Please, select three (3) neutral for this 
question.  
12. Your laboratory is likely to increase 
automation testing to reduce over test-
utilization (i.e. reduce repeat testing due to 
human error). 
13. Your laboratory is likely to increase 
molecular and genetic testing to personalize 
medical care for the individual patient (i.e. 
individualized testing ordering based on 
history, algorithms and clinical information).  
14. Automation testing is likely to promote 
shared information of test results in your 
laboratory (i.e. seamless transmission of 
tests results between institutions).  
15. Your laboratory has experienced an 
improvement in patient outcomes (i.e. 
improved disease detection, prevention and 
or delayed onset of diseases). 
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Table 1 (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RQ3: Are the variables Technology-C, 
Utilization-C, and Reimbursement 
appropriately measuring the latent variable 
“Cost” as a disrupter to the iron triangle? 
16. Your laboratory has incorporated 
evidence-based medicine to support better 
patient outcomes (i.e. eliminate unnecessary 
testing).  
17. Your laboratory is likely to experience 
an increased value-based care that focuses 
on test ordering that is beneficial and 
necessary for the patient (i.e. Evidence-
based laboratory medicine; right test, for the 
right patient, at the right time).   
18. Your laboratory has experienced an 
increase in information technology to 
support personnel (i.e. assist with high 
throughput and complex test result 
interpretations). 
19. Your laboratory invests in educating 
personnel to improve competence (i.e. 
continuing education program, professional 
society membership and publications). 
20. Your laboratory supports personnel 
earning advanced degrees to improve 
laboratory and provider relationship (i.e. 
consultation support of test results). 
21. Please, select one (1) Strongly Agree for 
this question.  
22. Your laboratory is likely to maximize 
miniaturization of assay technology to 
support high volume throughput tests as a 
cost-effective strategy. 
23. Electronic medical records in your 
laboratory are likely to decrease 
administrative cost (i.e. streamline data; 
reduce redundancy, allow seamless access to 
patients results in different geographical 
areas). 
24. Your laboratory is likely to use or 
incorporate the use of bar coding technology 
to minimize misidentification test results. 
25. Your laboratory is likely to implement a 
wide range of molecular diagnostic tests to 
support the increase of the elder population 
with insurance. (i.e. Tests that provides less 
expense and greater availability.  
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Table 1 (continued). 
 26. Your laboratory is likely to experience 
an increase in novel health care delivery 
systems to reduce costs for patients (i.e. 
Accountable care organization, State 
Innovation Models, etc.). 
27. Your laboratory is likely to experience 
an increase in competitive bidding for 
laboratory tests (i.e. quote the best price with 
the best quality to gain customers).   
28. Your laboratory is not likely to 
experience patient co-payment fees for 
laboratory tests (patient provides a co-
payment to the laboratory upon visit). 
29. Your laboratory is likely to experience 
an increase in the bundled payment method 
to reduce cost (aligning the services and 
goals of the patients, providers, and all 
parties involved to improve quality and 
reduce cost). 
30. Your laboratory is likely to experience a 
decrease in Fee-for-service billing to curb 
cost. 
Note: This table explains the correlation of the research questions to the survey questions regarding the constructs of access, cost and 
quality operationalized in the study.  
The survey was generated using the Qualtrics survey platform with the support of 
USM staff. The target population was 250,000 CLIA affiliated clinical laboratories 
throughout United States. From the targeted population, only 2,124 electronic surveys 
were sent out to obtain a sample. Of the 2,124 surveys sent out, only160 surveys were 
considered useful for the study. The goal was to obtain a diversity of laboratory managers 
and directors’ perspectives across all geographical areas regarding the impact of PPACA. 
Once the survey responses were received, the first step was data screening to account for 
missing data to prevent systematic bias. Data screening was followed by assumptions and 
diagnostics of the data to correct for normality, outliers, linearity and homoscedasticity. 
Finally, if the data had outliers, the outliers were accounted for by using methods such as 
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transformation, z-scores, and truncation to correct these abnormalities. IBM SPSS 23 and 
IBM SPSS AMOS 23 statistical software analyzed the data, using the statistical method 
SEM with the goal of creating the most parsimonious model. 
Operationalization of the Model 
Figure 7 provides a diagram of the predicted model derived from the theory of the 
iron triangle on clinical laboratories. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Predicted Model  
The figure provides an illustration of the predicted model as a disrupter to the iron triangle of health care in the laboratory. The oval 
shapes represent the latent variables and the rectangle shapes represent the indicator variables in the model. The circle shapes 
represent the error variance in each latent and observed variable. Each latent variable is described by three indicator variables were 
arrows denotes these relationships.in the model. The double errors between error variances show there are shared error variances 
amongst the indicator variables.  
The operationalization of these constructs used Likert scales to measure the 
constructs and assess the efficacy of clinical laboratories post implementation of the 
PPACA. The range of the Likert scales is as follows: using a 5-point scale (l=Strongly 
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agree, 2=Agree, 3=Neutral, 4=Agree, 5=Strongly disagree,) with a non-applicable option 
(6= Non-applicable). The constructs and operationalization of measurement for the 
laboratories are derived from the ideas of many laboratorians and organizations within 
the laboratory field. The drivers of these indicators express the concepts that are 
occurring now in laboratories and what is projected to happen in the near future. The 
ultimate goal of PPACA is to increase Access, increase Quality, and reduce Cost 
simultaneously for all American citizens. This achievement can be summed up as 
follows: 
Access. Access describes the availability of having insurance coverage for 
healthcare when it is needed for the individual patient. To achieve an increase in Access, 
healthcare insurance must be provided to individuals with preexisting health conditions, 
individuals and families that fall below a certain cap of the federal poverty line are 
granted subsidies, and previous noninsured individuals must have access to clinical 
laboratory testing. For this report, the indicators of Reform, Fee, and Utilization assessed 
Access. The written equation of Access Operationalized: [Reform (Increase to screening 
tests, Increase access to diagnostic tests)] + [Fee (Decrease cost for individuals seeking 
healthcare, the impact of reimbursement rates from the Center for Medicare/Medicaid 
System on clinical laboratories financial viability)] + [Utilization (Availability of new 
testing to support the increase of individuals with insurance)]. 
Quality. Quality refers to both statistically measured and real treatment outcomes. 
It includes the understanding to develop real standards of acceptable practice that makes 
a difference to patients. To achieve an increase in quality the use of smart technology 
must improve the overall care of the patient, providers must deliver individualize health 
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care to the patient, and laboratories must use evidence-based medicine to benefit patients. 
For this report, the indicators Technology, Patient Safety, and Personnel assessed 
Quality. The written equation of Quality Operationalized: [Technology (Automation of 
Molecular Testing to avoid human errors for test interpretations and improve efficiency 
of testing for the individual patient)] + [Patient Safety (Effectiveness Studies, Patient-
centered care that benefits the patient)] + [Personnel (Invest in human capital to improve 
provider-patient relationship of laboratory tests)]. 
Cost. Cost is associated with the affordability of healthcare for patients and payers 
at a given rate. To achieve a decrease in cost for this report, the indicators Technology, 
Utilization, and Reimbursement assessed Cost. The written equation of Cost 
Operationalized: [Technology (Genetic and predictive testing + Information technology)] 
+ [Utilization (Aging population + Expansion of test menu)] + [Reimbursement (Co-pay 
+ for laboratory testing, Bundled Payment)]. 
Model Building 
First Step. The first step is model specification that involves hypothesizing the 
model based on being a disrupter to the theory of the iron triangle in clinical laboratories 
(see Figure 7). This step recognizes the relationships between the observed variables as 
compared to relationships of the variables within the predicted model. For this study, 
clinical laboratory managers and directors rated 30 items on a five (5)-point Likert scale; 
from strongly agree to strongly disagree regarding their beliefs and experiences of the 
PPACA on clinical laboratories post implementation. In addition, a Likert scale with the 
option (non-applicable) was offered for questions that are not relevant to the participants 
and was coded as missing.  
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Second Step. The second step is Model identification, fitting a structural equation 
model to the data. In this step, the difference between the number of variables and the 
number of parameters in the model must be estimated. This estimation is achieved by 
generating the following parameters in the model: (a) pattern and structure coefficients of 
the independent and dependent variables (b) the coefficient correlation relationships 
between the independent variables in the model (c) and the variance of the independent 
variables variance must be determined (Myers, Gamst, & Guarino, 2013a,). To calculate 
these parameters the number of nonredundant and unknown elements must be 
premeditated (Bentler & Chou, 1987). According to Raykov & Marcoulides (2000), these 
nonredundant elements can be calculated by using the formula V (V+1)/2, where the (a) 
covariance or correlation matrix are counted for the dependent variables (b) and variances 
and coefficients for the paths of the independent variables are counted (p.757). For the 
unknown elements in the model (a) the variance of the latent (construct) variables (b) the 
variance of the unique error variances (c) pattern/structure coefficients of the latent 
(construct) variables (d) and the pattern/structure coefficients relating to the unique error 
variables (Myers et al., 2013a, pp. 850-871). With this situation, it is important to have 
more knowns than unknown parameters, because the unknowns are subtracted from the 
knowns creating a positive unique solution. This positive solution (positive degrees of 
freedom) creates an over-identified model, which permits the calculation of fit statistics 
for the evaluation of the model. Negative solutions (under identified) or even solutions 
(just defined) will not permit meaningful analysis to be performed; therefore, the analysis 
of the model cannot progress until an over-justified model is created (Bentler & Chou, 
1987). 
 48 
Evaluation. Once a structural equation model is specified and the free parameters 
estimated; then the fit of the proposed model to the actual data is evaluated. There are 
multitudes of fit indices available to evaluate the model. Traditionally, Chi-square (an 
absolute fit index) is used to assess the difference between the predicted and observed 
interrelationship in the model. Since most researchers are predicting a close fit between 
the predicted and observed model, the desired outcome is to have a non-significant Chi-
square. Chi-square works well with relative small cases approximately 75-200; however, 
as cases increase so does the power of Chi-square, which is likely to produce a type II 
error (Myers et al., 2013a, pp. 850-871). For this reason, other fit indices categorized as 
absolute, relative, and parsimony are used in addition with Chi-square to assess the 
model. 
Just as Chi-square, the root mean square error of approximation (RMSEA) is an 
absolute fit index. The RMSEA differs from the Chi-square in that it interprets the 
average residuals of the covariance/correlations matrix between the predicted and 
observed model (Myers et al., 2013a, pp 850-871). Therefore, it assesses the 
approximation of error in the sample and precision. Values equal to or less than .08 are 
considered acceptable values for RMSEA. Values greater than .10 are considered 
unacceptable values in some instances and must be followed up with theory and 
principle-driven decisions to accept or reject (Myers et al., 2013a, pp 850-871). In 
addition to the range of values for RMSEA, the 90% confidence interval is reported to 
present an accurate picture of the absolute fit index.  
Relative fit indices are used as well in this study. Relative indices measure the 
observed versus the predicted fit based on an incremental continuum of the worst fit (no 
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relationship) to a perfect fit (statured relationship) rather than a one-time measurement as 
the absolute indices. The relative indices that were used in this study are the comparative 
fit index and the Tucker-Lewis Index. Values greater than .95 are considered acceptable 
as a good fit for the model regarding both relative indices. Values less than .90 are 
considered inadequate for the model (Myers et al., 2013a, pp 850-871). 
There are numerous other fit indices available to the researcher through software 
packages that assist in assessing the predicted model. The use of multiple model fit 
indices is essential in clarifying and providing a complete picture of complex prediction 
models such as SEM. When these fit indices are used collectively, they provide the 
researcher with a comprehensive analysis of the model. 
If the model does not have adequate fit, then the use of model re-specification and 
fit indices reevaluation are considered to improve the model. Depending on the theory 
used and researcher’s end state there may be several occurrences of model re-
specification. According to Joreskog (1993), only model creating would permit re-
specification after the initial hypothesized model has been estimated. Once a model is re-
specified, it becomes more of an exploratory procedure, such as exploratory factor 
analysis rather than a confirmatory procedure. In these exploratory procedures, new data 
must be captured to produce valid results.  
Data Analysis 
IBM SPSS Statistics 23 combined with AMOS 23 was used to draw and analyze 
the data collected in this study. The first step is data cleaning to ensure data are 
accurately in SPSS. From there, data cleaning occurred to account for patterns of missing 
data and to account for outliers. The next step, descriptive statistics was used to tabulate 
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responses, calculate percentages and means, account for normality, linearity, 
homoscedasticity, errors, and data transformation if needed. Analysis of Moment 
Structure (AMOS) was used to draw the predicted model. Confirmatory factor analysis 
was used to assess the responses of the indicators variables in relation to the latent 
constructs (Quality, Cost, and Access) as described in the theory of iron triangle. Path 
analysis was used to assess the relationships between the predicted and observed latent 
variables, as well the relationships of both latent variables and their respective indicator 
variables in the model (Myers, Gamst, & Guarino, 2013b, pp. 974-981). 
Ethical Procedures 
For this study, all participants were informed that18 years or older, is the required 
age needed to engage in this study. The study purpose and procedure was reviewed with 
each participant before consent was confirmed. Data collection consisted of a survey with 
semi-structured, open-ended questions. Each participant was reassured that his/her 
responses and name would remain confidential. It was explained to each participant that 
withdrawal from the study at any point in the process is an option. Prior to collecting any 
data, permission was obtained from the Institutional Review Board (IRB). Data were 
analyzed accurately to align with participants’ survey responses and under no 
circumstance did misrepresentations occur. All data were held confidentially in a secure 
location and will be discarded after five years. 
Summary 
Chapter III provides a description of the quantitative research design and rationale 
for the study’s approach. Table 1 shows how the research questions related the survey 
questions. A detail description was given in how the construct variables were 
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operationalized and how the predicted model was created. Data collection procedures and 
data analysis were explained to together with data cleaning and data assumption 
techniques. Issues of trustworthiness and ethical considerations were also described in 
detail. 
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CHAPTER IV – RESULTS 
This quantitative study analyzed the impact of the PPACA on health care in the 
clinical laboratory. The impact of PPACA was measured on the constructs of Access, 
Cost, and Quality as it relates to the iron triangle of health care. Understanding the 
impacts of the new statute will help the laboratory community prepare and perform 
efficiently in the future. The purpose of this study was to analyze the impact of the 
PPACA on the clinical laboratory via SEM. Perhaps in understanding the impact of 
PPACA on the clinical laboratory can help (a) increase access to laboratory tests (b) 
provide a better quality of test results via an improved total testing process and (c) reduce 
the cost per laboratory test for the average citizen. This chapter summarizes the key 
findings obtained from the responses of 160 participants. The researcher analyzed these 
data using the Software from IBM SPSS 23 with the addition of AMOS 23. 
Demographics of Survey Respondents 
After carefully analyzing the contact list, the following demographic data results 
were calculated. For this study, 2,124 surveys were emailed to eligible laboratory 
managers and directors. Of the 2,124 surveys emailed, 247 (12%) were returned to the 
researcher. Of the 247 returned, 60 (23%) were incomplete and could not be used in the 
study, leaving 167 possible surveys. After data cleaning, three surveys were removed due 
to missing data and four were removed as outliers, leaving 160 surveys available for data 
analysis. These completed surveys were from all 50 states, including the District of 
Columbia, meeting the inclusion criteria for full analysis. Of these participants, the 
majority represented Hospital-based laboratories, see figure 8 for a statistical breakdown 
of the facilities involved in providing data for this study.  
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Figure 8. Type of Facility 
In addition, the 160 completed surveys reported with the following demographic 
distribution seen in Table 2. 
  
Demographics of Facilities and Participants 
How would you classify your institution? 
 
Facility Type                                                             Percentage %                    Count 
Public 70.09% 112 
Private 23.08% 37 
Unsure   6.84% 11 
   
How many laboratory tests does your laboratory perform annually? 
 
Number of tests per year Percentage% Count 
Less than 50,000 tests 4.31% 7 
50,000 to 100,000 4.78% 7 
100,000 to 250,000 tests 12.93% 21 
250,000 to 500,000 tests 14.66% 24 
> 500, 000 tests  54.31% 87 
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Table 2 (continued).  
Number of tests per year Percentage% Count 
Less than 50,000 tests   4.31% 7 
50,000 to 100,000 tests   4.70% 7 
 
Select years of experience as a laboratory Manager and/or Director 
 
Years of Experience                                                  Percentage %                    Count 
Less than one year   5.17% 8 
One to five years 13.79% 22 
Five to ten years 18.10% 29 
Ten to twenty years  37.93% 61 
> twenty years  25.00% 40 
 
Has your state expanded Medicaid under the PPACA? 
 
Medicaid Expanded                                                  Percentage %                    Count 
Yes 45.61% 73 
No 33.33% 53 
An expansion is planned in my state, but 
not yet in place 
  4.39% 7 
Unsure  16.67% 27 
 
Reliability of Survey 
Prior to conducting a full analysis of the data, it is important to access the 
reliability of the items on the survey that correlates with the construct variables (latent 
variables) and observe variables identified in the theoretical framework. There are three 
options regarding results obtained from reliability testing. (a) Accept the items on the 
survey as consistent with the variables then proceed to data analysis (b) modify the items 
on the survey to achieve acceptability then proceed to data analysis or (c) reject the 
survey because of the items listed cannot achieve reliability (Myers et al., 2013a).  
According to Myers et al. (2013a), the Cronbach’s alpha is traditionally the most 
dependable coefficient in accessing reliability amongst theory testing. Coefficient values 
that are .90s and above are considered excellent, high to middle values of .80s are very 
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good, values of low .80s are considered good, values high to the middle .70s are 
considered acceptable, .70s to middle .60s are considered borderline, and values of low 
.60s and below are considered problematic to unacceptable (p. 722). 
With these numbers in mind, the first level of assessing reliability is to evaluate 
the construct (latent) variables Access, Quality, and Cost with the 28 items on the survey 
(see Table 1). The construct variables (Access, Quality, and Cost) presented with 
Cronbach’s alpha coefficients of .656 acceptable for research, .825 good acceptable, and 
.712 acceptable, respectively. Although, for the construct variable Access, if Item 6 and 
or Item 7 were deleted from the instrument the Cronbach’s alpha would increase to .676; 
these items were kept to provide a broader explanation of access. 
The second level of accessing reliability is to evaluate the nine observed variables 
identified within the theoretical framework in this study. Those nine observed variables, 
along with the corresponding items on the survey, and Cronbach’s alpha coefficients 
presented with the following data in Table 3.  
  
Observed Variables Cronbach’s Alpha 
Observed Variable Survey Questions Cronbach’s Alpha 
Reform 1-4 .620 
Fee 5-7 .656 
Utilization-A 8-10 .682 
Technology-Q 12-14 .677 
Patient Safety 15-17 .632 
Personnel 18-20 .758 
Technology-C 22-24 .602 
Utilization-C 25-27 .659 
Reimbursement 28-30 .693 
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Although most of the observed variables Cronbach’s alpha coefficient fell within 
the range values from high to low .60s, the researcher deemed these values acceptable to 
further analyze the data. 
Data Screening and Diagnosis 
Laboratory managers and directors responses were evaluated with the 30-item 
Clinical Laboratory Managers Inventory Survey. Nine observed variables with three to 
four items per variable were created with the names, Reform, Fee, Utilization-A, 
Technology-Q, Patient Safety, Personnel, Technology-C, Utilization-C, and 
Reimbursement. All 30 items were scored on a 5-point summative response scale (1= 
strongly agree to 5= strongly disagree). Using descriptive statistics in SPSS the data were 
examined for missing data, skewness and kurtosis. The data presented with missing 
values of 2% or less, well below the tolerance limit of 5% preventing the intervention of 
missing value analysis; therefore, likewise deletions were used to remove cases with 
missing values. For univariate analysis, the data showed positive skewness for the 
majority of the observed variables with the exception of Reform, Patient, Utilization-C, 
and Reimbursement, which indicated symmetry. The data also presented with a mixture 
of kurtosis values (mesokurtic, leptokurtic and platykurtic) for all nine observed 
variables. Multivariate outliers were analyzed using Mahalanobis distance for each case 
regarding the nine observed variables. As a result, four cases were identified as outliers 
because they presented with p < .001 for Mahalanobis distance. These cases were 
removed from the dataset to prevent skewness and kurtosis of the data. The assessment of 
normality, homoscedasticity, and homogeneity of variance within the data displays 
normal distribution and equal variance across all variables. After successful screening 
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and performing diagnostic and assumption procedures on the data, the data are ready to 
proceed to data analysis.  
Data Analysis 
Research Question Q1  
Are the variables Reform, Utilization-A, and Fee appropriately measuring the 
latent variable “access” as a disrupter to the iron triangle? This question is answered by 
the responses to the survey questions 1-10 listed in table 1. As prior of research question, 
1 predicts an increase in access due to PPACA. Therefore, the responses from the 
participants on the survey regarding this research question should display answers that 
suggest choices of strongly agree to agree for the majority of the questions.  
Survey Questions 1-4. Survey questions 1-4 regarding the observed variable 
Reform in Figure 9, shows high percentages for the combination of responses for strongly 
agree and agree. Survey question 1 presented with a value of 65%, survey question 3 with 
a value of 58%, and survey question 4 with a value of 44% respectively. Survey question 
2, presented with different values than the expected a prior, with high a percentage for the 
combination response neutral and disagree at 48%. Although survey question 2 displayed 
different results than what was expected from the outcome, the full structural model 
coefficient weight for observed variable Reform presented with a value of .43 (p < .001). 
This value supports that the indicator variable Reform is measuring the latent variable 
access appropriately in the model. 
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Figure 9. Survey Questions 1-4 
Note: Illustration of the statistical breakdown in percentages by the question (1-4), regarding the 6-point Likert scale used to capture 
participant response.  
Survey Questions 5-7. These questions represent the indicator variable Fee as it 
relates to the research question 2. Figure 10 shows that high percentages for the 
combination response strongly agree and agree were achieved for survey question 5 at 
61%. Survey question 6 and survey question 7 showed high percentages for the 
combination response disagree and strongly disagree at 65% and at 57% respectively. 
The results from these survey questions are consistent with the predicted outcome. In 
addition, the full structural model coefficient for Fee presented with a significant value of 
-.16 (p = .031). This value is indicative in that the observed variable Fee is measuring the 
latent variable access appropriately. The coefficient value also provides evidence that the 
construct variable Cost is decreased per individual as it relates to Access.  
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Figure 10. Survey Questions 5-7 
Note: Illustration of the statistical breakdown in percentages by question (5-7), regarding the 5-point Likert scale used to capture 
participant response 
Survey Questions 8-10. These questions address the observed variable Utilization-
A as it relates to research question 1. The outcome of these survey questions is expected 
to produce high percentages for the combined choice strongly agree and agree. Figure 11 
displays the percentage of survey questions 8-10 at 51%, 47%, and 69% respectively, 
illustrating that the survey questions achieved the expected outcome. In addition to 
percentage outcome of the questions, the full structural model coefficient weight for the 
observed variable utilization A presented with a significant value of .57 (p < .001). This 
value is an indication that the observed variable Utilization A is measuring the latent 
variable Access appropriately, as predicted by the model. 
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Figure 11. Survey Questions 8-10 
Note: Illustration of the statistical breakdown in percentages by the question (8-10), regarding the 5-point Likert scale used to capture 
participants’ responses. 
Research Question Q2: 
Are the variables Technology-Q, Patient Safety, and Personnel appropriately 
measuring the latent variable “quality” as a disrupter to the iron triangle? Survey 
questions 12-20 as seen in Table 1 are used to assess research question 2. Results from 
these questions are expected to indicate an increase in quality as it relates to an increase 
in access regarding the iron triangle of health care in the laboratory. Therefore, the 
majority of the responses to these questions should reflect answers that correspond with 
strongly agree to agree. 
Survey Questions 12-14. These questions regarding the indicator variable 
technology Q in Figure 12 displays high percentages for the combination response 
strongly agree and agree. Survey question 12 presents with a value of 78%, survey 
question 13 with a value of 76%, and survey question 14 with a value of 72%; 
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respectively. The full structural model coefficient for Technology Q presented with a 
significant value of .64 (p < .001). This value is indicative the indicator variable 
Technology Q measuring the latent variable quality appropriately.  
 
Figure 12. Survey Questions 12-14 
Note: Illustration of the statistical breakdown in percentages by the question (12-14), regarding the 5-point Likert scale used to capture 
participant response. 
Survey Questions 15-17. These questions address the responses for the indicator 
variable Patient Safety, as it relates to research question 2. Strongly agree and agree are 
the expected responses from these questions. In Figure 13 the data displays high 
percentages for combined choices agree and neutrality for question 15 at 74%, slightly 
different from the expected responses for this question. Question 16 and question 17 
presented with a high percentage of the combined choices of strongly agree and agree at 
72% and 77% respectively. The full structural model coefficient for Patient Safety 
presented with a value of .82 (p < .001). This value indicates the substantial strength of 
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survey questions 15-17for the observed variable patient safety, and that the observed 
value (patient safety) is measuring quality appropriately. 
 
Figure 13. Survey Questions 15-17 
Note: Illustration of the statistical breakdown in percentages by the question (15-17), using a 6-point Likert scale to capture participant 
responses. 
Survey Questions 18-20. These questions address the responses for the indicator 
variable Personnel as they relate to research question 2. Strongly agree and agree 
combined choice from the instrument is posited to receive high percentages for survey 
questions 18-20. Figure 14 displays the results of these questions, with response 
percentages of 61%, 80%, and 70% respectively. In addition, the full structural model 
coefficient weight for personnel presented with a value of .66 (p < .001). This value 
indicates the substantial strength of questions 18-20 as good indicators for the observed 
variable Personnel, and that the observed variable (Personnel) is measuring the latent 
variable Quality appropriately.  
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Figure 14. Survey Questions 18-20 
Note: Illustration of the statistical breakdown in percentages by the question (18-20), using a 6-point Likert scale to capture participant 
responses. 
Research Question Q3: 
Are the variables technology-C, utilization-C, and reimbursement appropriately 
measuring the latent variable “cost” as a disrupter to the iron triangle? Questions 22-30 
on the instrument are used to address research question 3. The responses of questions 22-
30 are expected to have a high combined percentage of choices strongly agree and agree. 
The overall analysis of the data is expected to produce results that decrease the latent 
variable cost as it pertains to the effects of PPACA.  
Survey Questions 22-24. These questions on the survey address the observed 
variable Technology-C as it pertains to the latent variable cost. The Outcome of the 
responses for these questions is expected to have high percentages for the combined 
choices of strongly agree and agree. As seen in Figure 15, these results hold true to 
expected outcome as questions 22-24 present with the following percentages of 59%, 
 64 
58%, and 80% respectively. The full structural model also supports the predicted 
outcome, with a coefficient weight for Technology C presenting with a value of .34 (p < 
.001). This value indicates the modest strength of questions 22-24for the observed value 
technology C; therefore holding true that Technology C measures the latent variable Cost 
appropriately.  
 
Figure 15. Survey Questions 22-24 
Note Illustration of the statistical breakdown in percentages by the question (22-24), using a 6-point Likert scale to capture participant 
responses.  
Survey Questions 25-27. These questions are used to address the observed 
variable Utilization-C as it pertains to the latent variable cost. Expected outcome of the 
responses for these questions is to have high percentages for the combined choices of 
strongly agree and agree. As seen in Figure 16, these results hold true to expected 
outcome as questions 25-27 present with the following percentages 58%, 57%, and 50 % 
respectively. The full structural model coefficient for Utilization C presented with a value 
of .48 (p < .001). This value indicates the modest strength of questions 25-27for the 
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observed value Utilization C. The results of these questions are indicative that Utilization 
C is measuring the latent variable Cost appropriately. 
 
Figure 16. Survey Questions 25-27 
Note: Illustration of the statistical breakdown in percentages by the question (25-27), using a 6-point Likert scale to capture participant 
responses. 
Survey Questions 28-30. These questions address the observed variable 
Reimbursement as it refers to the latent variable cost. Expected outcome of the survey 
questions is to have high percentages for the combined choices of strongly agree and 
agree. As seen in Figure 17, these results hold true to expected outcome as questions 28-
30 present with the following percentages 53%, 72%, and 79 % respectively. The full 
structural model coefficient for Reimbursement presented with a value of .32 (p < .001). 
This value indicates a modest strength of questions 28-30 measuring the observed 
variable Reimbursement. The results of these questions indicate that the indicator 
variable Reimbursement is measuring the latent variable Cost appropriately. 
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Figure 17. Survey Questions 28-30 
Note: Illustration of the statistical breakdown in percentages by the question (28-30), using a 6-point Likert scale to capture participant 
responses.  
Research Question Q4: 
Is the goodness of fit between the predicted model and the observed data similar 
enough to explain the hypothesized relationships of the PPACA as a disrupter to the iron 
triangle? After carefully analyzing the data using structural equation modeling in SPSS 
and SPSS AMOS 23, the data analysis should support coefficients that indicate goodness 
of fit measures for Chi-square, GFI, TLI, CFI and RMSEA that are acceptable to begin 
full structure analysis. Prior to conducting the measurement model, the error variances 
within the model are correlated in accordance with theory and real-world practicality (see 
Figure 18).  
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Figure 18. Measurement Model with Correlated Error Variances 
The theoretical justification for the correlation of the error variances are as 
follows:  
1. The correlation of the error variance A1E (Utilization) with error variance 
Q2E (patient safety) makes theoretical sense. This makes sense because the 
utilization of diverse testing platforms, the use of new methodologies and 
diverse testing is likely to improve patient safety as the new provisions 
suggest; by means of improving disease detection, eliminate unnecessary 
testing and ensuring evidence-based medicine. 
2. The correlation of the error variance A1E (Utilization) with error variance 
A2E (Reform) makes theoretical sense. This makes sense because the 
implications of the reform laws within the PPAC is likely to improve the 
utilization of smart technology,  the utilization of new testing methodologies, 
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and the utilization of evidence medicine based medicine on managing the 
influx of new patients within the healthcare system. 
3. The correlation of error variance C1E (Reimbursement) with error variance 
C2E (utilization) is theory applicable. This is practical in the sense that 
increasing utilization of novel healthcare delivery systems to reduce costs in 
accordance with PPACA is likely to encourage laboratories to decrease the 
practice of other legacy delivery systems (i.e. fee for services). 
4. The correlation of error variance C3E (technology) with error variance Q1E 
(personnel) is justifiable. This is practical in the sense that laboratory 
personnel receiving higher education are likely to provide better consultation 
support to the physician regarding complex test interpretations. 
5. The correlation of error variance Q1E (personnel) with error variance Q2E 
(patient safety) makes theoretical sense. This is practical in the sense that 
laboratory personnel will use information technology to support high 
throughput testing while maintaining high quality due to the provisions in the 
PPACA. 
6. Correlating error variance C1E (reimbursement) with error variance Q2E 
(patient safety) is practical to theory. The reimbursement methods associated 
with the PPACA indirectly affects the type of service provided to improve 
patient outcomes. The new initiatives within the PPACA encourage the use of 
bundled payment services, where primary care providers share ideas to 
provide each patient the absolute best care available, without overcharging for 
the service provided.  
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7. Correlating the error variance A2E (reform) with error variance C1E 
(reimbursement) theoretically, make sense. Provisions within PPACA 
promote bundled reimbursement methods, where coordinated efforts for 
healthcare services are provided throughout the full spectrum of care. The 
payment for the services is then divided amongst providers; therefore all 
parties involved (patient, provider, and insurer) are aligning healthcare 
outcomes with quality benchmarks.  
The data from the measurement model displayed a chi-square of 33.5 (17) p = 
.001. The GFI had a value of .958. The RMSEA presented with a value of .078 with a 
90% CI [.037 to .117]. The TLI presented a value of .929 and the CFI presented with 
value of .966. See Table 4 for a full display of the goodness of fit model indices. 
  
Measurement Model Fit Indices 
Fit Index Value Score Fit 
Chi-square 33.5/(df=17) 1.97 Good Fit 
GFI .958 NA Acceptable 
CFI .966 NA Good Fit 
TLI .929 NA Good Fit 
RMSEA .078 CI 90%(.037 to .117) NA Good Fit  
Note: The abbreviation NA = Non-Applicable meaning the fit index does not have a score that corresponds to the category. The 
abbreviation df= degrees of freedom within the model. The abbreviation CI= Coefficient interval.  
The correlation of latent variables range from .703 to .784, this is indication that 
the measured variables are good indicators of their respective factors. This also suggests 
that the latent variable correlations did not exceed .80 indicating that collinearity is not an 
issue.  
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In addition, the correlated error terms displayed significant correlations weights 
ranging from -.181 to 1.454.provding veracity that these correlations are meaningful in 
justifying the theory. See table 5 for all correlated error terms and correlations weights. 
  
Correlations of Error Variances 
Factors and Error Variances Correlation Value p value 
QUALITY <--> COST 1.454 <.001 
C1E <--> C2E .513 <.001 
Q1E <--> C3E .207 .012 
Q1E <--> Q2E .293 .049 
Q2E <--> C1E -.181 .017 
A1E <--> A2E .328 .116 
Q2E <--> A1E .253 .008 
C1E <--> A2E .190 .005 
 
These fit indices and correlated error variances demonstrated a good fit for the 
measurement model; therefore, the predicted model can be further evaluated as a full 
structural model. 
Full Structural Model Analysis 
The full structural analysis presented with a chi-square value of 33.5 (17) p = 
.010. The GFI, CFI, and TLI were 958, .966, and .929, respectively. The RMSEA 
presented with a value of .078 with a 90%CI (.037 to .117). These fit indices are 
equivalent to the fit statistics seen in the measurement model. Based on these indices, the 
model indicates a good fit to the data. In addition, the coefficient estimates, 
unstandardized and standardized regression weights were obtained from the analysis. 
These Beta coefficients ranged from -.16 to 1.70 indicating respectable indicators of their 
respective latent factors. See Table 6 for a complete detail of the fit indices and Beta 
coefficients of the full structural model. 
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Full Model Fit Indices 
Fit Index Value Score Fit 
Chi-square 33.5/(df=17) 1.97 Good Fit 
GFI .958 NA Acceptable 
CFI .966 NA Good Fit 
TLI .929 NA Good Fit 
RMSEA .078 (CI 90% .037-.117) NA Good Fit 
 
Standardize Regression Weights 
Construct and Indicator Beta Value p Value 
ACCESS                              COST -.469 .121 
ACCESS                              QUALITY 1.681 <.001 
Personnel                             QUALITY .658 <.001 
Patient Safety                       QUALITY .818 <.001 
Technology-Q                      QUALITY   .641 <.001 
Utilization-A                        ACCESS .536 <.001 
Reform                                 ACCESS .427 <.001 
Fee                                       ACCESS -.159 .031 
Reimbursement                    COST .320 <.001 
Utilization-C                        COST .477 <.001 
Technology-C                      COST .335 <.001 
 
Summary 
Chapter IV presents the findings of PPACA on clinical laboratories as it relates to 
the theory of the iron triangle. The findings present as follows (a) the observed variables, 
technology-Q, patient safety, and personnel appropriately measured the latent variable 
quality as a disrupter to the iron triangle. (b) The observed variables technology-C, 
utilization-C, and reimbursement appropriately measuring the latent variable “cost” as a 
disrupter to the iron triangle. (c) The observed variables technology reform, utilization-A, 
and fee appropriately measured the latent variable “access” as a disrupter to the iron 
triangle. (d) Confirm that the indicators, reform, utilization-A, and fee measured the 
construct “Access” together with the latent variables, Cost, and Quality as 
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operationalized in this study. (e) Confirmed that the goodness of fit between the predicted 
model and the observed data similar enough to explain the hypothesized relationships of 
the PPACA as a disrupter to the iron triangle. 
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CHAPTER V – DISCUSSION 
This is the first quantitative study devoted to developing a comprehensive survey 
to evaluate the effects of PPACA on clinical laboratories. The study collected data from 
160 CLIA certified hospital-laboratories, physician-based laboratories, and reference 
laboratories throughout all 50 states. The design of the survey used the theory of the iron 
triangle to assess the relationships of Access, Cost, and Quality. The results of the study 
will potentially help laboratory managers assess the implications of PPACA on 
laboratories today, and provide the laboratory community with a plausible instrument to 
assess the influence of PPACA for subsequent research in the future.  
The structural model shown schematically in Figure 18 assessed the direct and 
indirect effects of nine observed variables and three latent variables on PPACA as a 
disrupter to the theory of the iron triangle in laboratories. The model consisted of the 
following three structural equations: The first predicted equation is that cost in relation to 
access would decrease due to the implementation of PPACA on clinical laboratories. 
Secondly, the predicted equation is that quality in correlation to access would increase as 
to the effects of PPACA. Thirdly, it is predicted that cost and quality would directly 
increase access to laboratory healthcare because of PPACA. In addition, it was 
hypothesized that the exogenous variables Cost and Quality would be positively 
correlated.  
Each of the latent variables was measured with three indicator variables as 
illustrated in the measurement model in Figure 18. The indicators of Access were 
measured by the new statutes in the PPACA: Increase testing (Utilization A), mandatory 
enrollment for all citizens (Reform), and the amount of cost per individual (Fee). The 
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indicators of Quality were assessed by patient outcome: Patient outcome based on 
employees competency (Personnel), use of electronic information to improve care 
(Technology), and use of evidence-based medicine to benefit patient (patient safety). 
Advances in new technology and payment methods assessed the indicators of cost: The 
use of molecular testing to provide better throughput, better flexibility and less expense 
(Utilization C), Prevention of human errors (Technology C), and the incorporation of 
novel repayment methods (reimbursement).  
A two-step structural equation modeling strategy was used to assess the predicted 
model. The first step used the measurement model (confirmatory factor analysis) to 
assess how well the indicator variables measured the latent variables in the model. As 
well, the measurement model provides convergent confirmation and discriminant validity 
of latent variables in the model. The measurement model used five criteria to assess the 
model fit. The chi-square test, which was statistically significant, χ2 (24, N = 160) 113.40, 
p < .001indicating that the model failed to fit the data. However, chi-square is affected by 
strong correlations of the factors, which are presented in the model. Equally, if the 
alternate option was used to capture the chi-square, (dividing the chi-square by the 
degrees of freedom 113.4/24 = 4.7; an acceptable fit is considered between 2 and 5) then 
it is suggested as an acceptable fit (Marsh & Hocevar, 1985). For this study, the alternate 
option was used to adjust for strong correlations regarding the chi-square. The goodness 
of fit index (GFI), the comparative fit index (CFI) and Tucker-Lewis index (TLI) were 
.864, .818 and .742 respectively for the measurement model, indicating adequate to poor 
fit. The root mean square error of approximation (RMSEA) was .153 with a 90% 
confidence interval of .125 to .182. The RMSEA with a value greater than .10 is 
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considered borderline acceptable; however, the RMSEA is possibly inflated due to 
sample size less than 200 (Paxton, Hipp, & Marquart-Pyatt, 2011). All coefficients within 
the model achieved statistical significance (p < .05) as well as real world significance 
(values >.30). Lastly, the correlations between the latent variables presented with values 
ranging from .70 to .78, indicating substantial discriminant validity amongst the latent 
variables. No modifications were made to improve the measurement model because of a 
prior theory justification and suitable coefficient weights for the model.  
The next step was conducting the full structural analysis of the predicted model. 
All indicator variables, latent variables along with the correlation of the indicator variable 
error variances are presented in Figure18. The overall results of the full structural model 
presented with an excellent fit. Using the alternate method suggested by Marsh and 
Hocevar (1985) the χ2 (17, N =160) =33.5, p = .010 resulted with a value of 1.97 (33.5/17 
= 1.97). The GFI, CFI, and TLI values were .958, .966, and .942 respectively. The 
RMESA was .078 with a 90% CI (.037 to. 117). Overall, the model explained 75% of the 
variance of Access regarding healthcare in the laboratory; indicating the model was an 
excellent fit to the predicted data regarding PPACA on clinical laboratories. Mostly, 
Access was driven by the direct influence of Quality, with an increasing relationship as 
predicted by PPACA. Cost did not show a significant effect on Access; however, it did 
show a decreasing relationship to Access as predicted by PPACA.  
Interpretation of Data 
After analyzing the data, it is apparent that clinical laboratories have adjusted 
their business practices regarding the implementation of the PPACA. Data suggest that 
the PPACA (a) increased access to laboratory tests (b) provided a better quality of test 
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results via an improved total testing process and (c) reduced the cost per laboratory test 
for the average citizen in the United States. However, this data cannot be generalized to 
every laboratory in the United States because not all laboratories fall under the decree of 
CLIA.  
The data in questions 1-30 in correlations with the research questions 1-3in Table 
1, along with the Figures 9-17, demonstrates that the observed data confirms the accuracy 
of the hypothesized data. With the majority of the results showing a combination 
response of strong agree and agree questions 1-30. In addition, the nine observed 
variables that measured the three latent variables (access, cost and quality) provided 
coefficient regression weights ranging from -.16 (modest indication) to .82 (substantial 
indication) with significant p<.05 values that the survey items are sufficient indicators of 
the constructs variables post implementation of the PPACA.  
Furthermore, the relationship between the construct variables Quality and Access 
provided substantial coefficient weights indicating an increasing relationship as predicted 
by the model. Although Cost did not provide a significant coefficient value, it did show a 
decreasing relationship between the construct variable Access as predicted. Data also 
show that 45.6% of the states in the U.S (as seen in Table 2) have expanded their 
Medicaid Programs to help individuals purchase health insurance; with an additional 
4.4% of non-committed states have future plans to expand their Medicaid programs to 
support PPACA.  
The total outcome of the study confirms that the Ho is true: There is no significant 
difference in the variables interrelationships between the predicted model and the 
observed model data set; therefore, this survey will serve as a plausible instrument to 
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assess the PPACA. In addition, the series of provisions brought on by the Patient 
Protection Affordable Care Act have encouraged clinical laboratories; to generate best 
operational practices that foster an atmosphere of increase access and quality, while 
simultaneously decreasing cost. Therefore, the PPACA acts as a disrupter to the iron 
triangle of health care in the clinical laboratory. 
Recommendation for Future Research 
Additional research should be conducted to fully explore the recommendations 
listed below. Addressing these recommendations will allow this instrument to be a 
stronger assessment tool to evaluate the effects of PPACA on the laboratory in the future. 
Perhaps this tool can help laboratory managers and directors strategically use different 
ways and means to create better patient outcomes. 
1. Although the fit indices, coefficient regression weights, and total variance 
showed an excellent fit for the full structural model, the measurement model 
fit indices were adequate to poor. This fact raised an interesting question that 
requires an investigation: What does it mean to have a full structural model 
that fits well and accounts for a large amount of variance, but have an 
adequate to poor measurement model? Perhaps this is attributed to the number 
of subjects used in the model. According to Raykov and Marcoulides (2006), 
the fit indices for SEM models are more favorable to larger data sets greater 
than 200 particular for the fit index RMSEA. In this study, the data set 
consisted of 160 participants; the small data set may have created significant 
fit indices for the measurement model, when possibly none exists. However, 
for the full structure model, the error variances were correlated with one 
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another, in accordance with the theory of the iron triangle of health care in the 
laboratory, and real-world practicality. Therefore, the fit indices and 
regression weight coefficients improved significantly for the full structural 
model to present with an excellent fit. Alternatively, perhaps this is due to the 
theory of the iron triangle, where the relationships of the three constructs are 
tightly interlinked. As a result, the correlations coefficient weights of each 
construct would create substantial weights in the model, thus producing poor 
fit indices when none exists (Kenny, 2003).  
2. The reliability scores (Cronbach’s Alpha) of the items on the Clinical 
Laboratory Manager Inventory survey were borderline adequate, indicating 
the consistency of the same responses for the items amongst participants was 
marginal. This finding possibly concluded that the items of the survey may 
have been too vague and requires more detail information to improve the 
consistency of the answers. Perhaps an item correlated with a construct should 
be moved to another construct, or deleted from the inventory. Likewise, it 
may indicate that the data set of 160 participants was not large enough to build 
a consistent amount of responses for each item on the survey.  
3. Recommend this study use the mixed method approach. This method allows 
the researcher to gather an in-depth feel for each item on the survey. It also 
gives the researcher the opportunity to employ the senses of listening and 
seeing subjective responses first hand, therefore enabling the researcher to 
analyze the data from multiple perspectives.  
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APPENDIX A – Clinical Laboratory Managers Inventory  
CLINICAL LABORATORY MANAGERS INVENTORY  
CONDUCTED BY: 
Harry McDonald Jr,  
Center for Science Education,  
University of Southern Mississippi 
 
YOUR RESPONSES TO THIS SURVEY ARE CONFIDENTIAL 
Individual participants will not be identified by name in any analyses or reports.  
Responses will be aggregated and reported as summary statistics only.  
 
 
FOR QUESTIONS PERTAINING TO THIS SURVEY, CONTACT:  HARRY 
MCDONALD JR, PRIMARY INVESTIGATOR, (xxx) xxx-xxxx or 
x.xxxxxxxxx@usm.edu 
 
PLEASE RETURN THE SURVEY AT YOUR EARLIEST CONVENIENCE. 
 
YOUR ASSISTANCE IS VERY MUCH APPRECIATED. 
 
PPACA 
Welcome to the Patient Protection Affordable Care Act Survey regarding clinical 
laboratories!    
 
Use the scale below to determine the one phrase that best represents your laboratory 
response post implementation of the Patient Protection and Affordable Care Act. Using 
the following scale, please indicate whether you agree or disagree with the following 
statements: 
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Please answer, the questions as they relate Reform to Access post implementation of the 
Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
1. Your laboratory is likely to 
increase screening tests such as 
HIV, Hepatitis B, Lipid Profiles 
etc.  
            
2. Your laboratory is likely to 
incorporate direct access testing 
(i.e. patients are able to request test 
results directly from the 
laboratory).  
            
3. Your laboratory is likely to 
experience an increase in first-time 
insurance users.  
            
4. Your laboratory is likely to 
experience an increase in state 
funding due to Medicaid 
expansion.  
            
 
Please answer, the questions as they relate Fee to Access post implementation of the 
Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
5. Your laboratory is likely to 
experience a decrease per 
individual cost for testing.    
            
6. The impact of reduced 
reimbursement rates is not likely to 
affect the financial viability of 
your laboratory (i.e. lower rates for 
the clinical laboratory fee 
schedule, sequestration cuts, 
adjustments to the consumer price 
index etc.).   
            
7. Your laboratory is likely to 
experience an increase in the 
prospective payment system (i.e. 
set amount per patient, regardless 
of the amount of care received).  
            
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Please answer, the questions as they relate Utilization to Access post implementation of 
the Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
8. Your laboratory is likely to 
incorporate a wide range of 
different laboratory tests to 
accommodate the projected 
increase in the elderly population 
(i.e. 65 and older).  
            
9. Your laboratory is likely to 
experience an increase in 
miniaturization of assay methods 
to expand the test menu (i.e. lab-
on-a-chip and point of care 
testing).  
            
10. Your laboratory is likely to 
experience an increase in new 
testing platforms to improve 
efficiency (i.e. core lab concept).  
            
 
Please answer, the questions as they relate Technology to Quality post implementation 
of the Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
11. Please select three (3) neutral 
for this question.   
            
12. Your laboratory is likely to 
increase automation testing to 
reduce over test-utilization (i.e. 
reduce repeat testing due to human 
error).  
            
13. Your laboratory is likely to 
increase molecular and genetic 
testing to personalize medical care 
for the individual patient (i.e. 
individualized testing ordering 
based on history, algorithms and 
clinical information).  
            
14. Automation testing is likely to 
promote shared information of test 
results in your laboratory (i.e. 
seamless transmission of tests 
results between institutions).  
            
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Please answer, the questions as they relate Patient Safety to Quality post 
implementation of the Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
15. Your laboratory has 
experienced an improvement in 
patient outcomes (i.e. improved 
disease detection, prevention and 
or delayed onset of diseases).   
            
16. Your laboratory has 
incorporated evidence-based 
medicine to support better patient 
outcomes (i.e. eliminate 
unnecessary testing).  
            
17.  Your laboratory is likely to 
experience an increase in value-
based care that focuses on test 
ordering that is beneficial and 
necessary for the patient (i.e. 
Evidence-based laboratory 
medicine; right test, for the right 
patient, at the right time).   
            
 
Please answer, the questions as they relate Personnel to Quality post implementation of 
the Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
18. Your laboratory has 
experienced an increase in 
information technology to support 
personnel (i.e. assist with high 
throughput and complex test result 
interpretations).  
            
19. Your laboratory invests in 
educating personnel to improve 
competence (i.e. continuing 
education program, professional 
society membership and 
publications).   
            
20. Your laboratory supports 
personnel earning advanced 
degrees to improve laboratory and 
provider relationship (i.e. 
consultation support of test 
results).   
            
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Please answer, the questions as they relate Technology to Cost post implementation of 
the Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
21. Please, select one (1) Strongly 
Agree for this question.   
            
22. Your laboratory is likely to 
maximize miniaturization of assay 
technology to support high volume 
throughput tests as a cost-effective 
strategy. 
            
23. Electronic medical records in 
your laboratory are likely to 
decrease administrative cost (i.e. 
streamline data; reduce 
redundancy, allow seamless access 
to patients results in different 
geographical areas).  
            
24. Your laboratory is likely to use 
or incorporate the use of bar 
coding technology to minimize 
misidentification test results.    
            
 
Please answer, the questions as they relate Utilization to Cost post implementation of the 
Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
25. Your laboratory is likely to 
implement a wide range of 
molecular diagnostic tests to 
support the increase of the elder 
population with insurance. (i.e. 
Tests that provides less expense 
and greater availability)     
            
26. Your laboratory is likely to 
experience an increase in novel 
health care delivery systems to 
reduce costs for patients (i.e. 
Accountable care organization, 
State Innovation Models, etc.).  
            
27. Your laboratory is likely to 
experience an increase in 
competitive bidding for laboratory 
tests (i.e. quote the best price with 
the best quality to gain customers).    
            
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Please answer, the questions as they relate Reimbursement to Cost post implementation 
of the Patient Protection Affordable Care Act. 
 1= 
Strongly 
 Agree   
2=Agree   3= 
Neutral     
4= 
Disagree   
5= 
Strongly 
Disagree      
9=NA  
28. Your laboratory is not likely to 
experience patient co-payment 
fees for laboratory tests (patient 
provides a co-payment to the 
laboratory upon visit).  
            
29. Your laboratory is likely to 
experience an increase in the 
bundled payment method to 
reduce cost (aligning the services 
and goals of the patients, 
providers, and all parties involved 
to improve quality and reduce 
cost).  
            
30. Your laboratory is likely to 
experience a decrease in Fee-for-
Service billing to curb cost.   
            
 
DEMOGRAPHICS   
Please provide the following demographic information regarding you and your institution 
by selecting one answer per question or filling in the blank space provided. 
 
1 Select your facility type: 
 1=Physician-Based Laboratory 
 2=Reference Laboratory 
 3=Hospital Based Laboratory 
 4=Other (Freestanding clinics, Referral testing laboratories, Walk in private clinics 
etc.)  
 
2 How would you classify your institution? 
 1=Public   
 2=Private  
 3=Unsure  
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3 How many laboratory tests does your laboratory perform annually?   
 1=Less than 50,000 tests   
 2=50,000 to 100,000 tests   
 3=100,000 to 250,000 tests  
 4=250,000 to 500,000 tests  
 5= > 500, 000 tests  
 
4 How long have you worked for this facility?  
 1=Less than one year   
 2=One to five years     
 3=Five to ten years    
 4=Ten to twenty years  
 5= > twenty years    
 
5 Select years of experience as a laboratory Manager and/or Director: 
 1=Less than one year   
 2=One to five years    
 3=Five to ten years   
 4=Ten to twenty years 
 5= > twenty years  
 
6 Please select your age range. 
 18-29 Years old  
 30-40 Years old  
 41-50 Years old  
 >50 Years old  
 
7 What is your certification affiliation?  Please select all that apply. 
o 1=ASCP  
o 2=NCA    
o 3=AMT  
o 4=Other  
o 5=None  
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8 Has your state expanded Medicaid under the PPACA? 
 1=Yes  
 2=No  
 3=An expansion is planned in my state, but not yet in place  
 4=Unsure  
 
9 Provide the name of your state in the space below 
____________________________ 
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APPENDIX B – Information Letter 
 
Harry McDonald Jr.  
Ph.D. Candidate, Science-Medical Laboratory Science    
University of Southern Mississippi 
 
Dear Mr. or Mrs.:  
I am Harry McDonald, a Clinical Laboratory Officer in the United States Army. I have 
17 years of medical laboratory science experience and have worked as the director and 
chief in numerous positions within the laboratory, and therefore, have firsthand 
knowledge of federal laws that influence clinical laboratory capabilities. I am conducting 
a study to design an instrument that will assess post implementation effects of the Patient 
Protection Affordable Care Act (PPACA) on clinical laboratories. The purpose of this 
study is to design the most theoretical, accurate instrument based on the theory of the iron 
triangle in order to assess the relationships of access, cost, and quality. The results of this 
study will help laboratory managers assess the implications of PPACA on laboratories 
today, and provide the laboratory community with a plausible instrument to assess the 
influence of PPACA for subsequent research in the future.  
 
Your name was purposefully selected from the list of the Clinical Laboratory 
Improvement Amendments Program. I would sincerely appreciate your help by 
completing the enclosed or attached questionnaire. The survey is anonymous and I will 
use pseudonyms to prevent disclosure of your information. I am interested in your honest 
opinion and your invaluable input to this study. If you prefer not to answer a question, 
please leave it blank.   
 
The survey should take approximately 15 minutes to complete. Participation can be in the 
form of an electronic survey, hardcopy, or telephonically depending on your preference. 
If you prefer the electronic survey, it will be sent to your e-mail address and can be 
conducted on any computer at your convenience. If you prefer a hardcopy, the survey 
will be sent to your preferred mailing address with an enclosed stamp envelope for your 
convenience to return the survey. If you prefer the survey be conducted telephonically, 
then a time can be arranged at your convenience. I would appreciate you returning the 
completed survey to me no later than January 15, 2017.  
 
Participation is voluntary and that refusal to participate will not result in any 
consequences. All participants have a right to confidentiality and can withdraw from the 
study at any time without any consequences. No names will be recorded and all data will 
be made anonymous by the researcher. Participants must be ages 18 or older and 
affiliated with the Clinical Laboratory Improvement Amendments Program to fill out this 
survey. If you have pertinent questions about the research and research subjects’ rights, I 
can be reached at the following: Ph. # xxx-xxx-xxxx, email: x.xxxxxxxx@edu.usm. 
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Thank you in advance for your cooperation with this important endeavor. Your answers 
will make significant contributions to our understanding of the contemporary and future 
issues that involves all of us regarding post implementation of PPACA on clinical 
laboratories. If you would like a summary of my findings, please send your request in an 
e-mail, and I will forward the findings to you when the study has been completed.  
Sincerely, 
Harry McDonald Jr, M.S. MLS (ASCP) SSB  
Ph.D. Candidate 
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APPENDIX C – IRB Approval Letter 
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APPENDIX D – Permission Letter for Figures 5 & 6 
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